<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Cell Mol Biol Lett</journal-id><journal-id journal-id-type="iso-abbrev">Cell Mol Biol Lett</journal-id><journal-title-group><journal-title>Cellular &#x00026; Molecular Biology Letters</journal-title></journal-title-group><issn pub-type="ppub">1425-8153</issn><issn pub-type="epub">1689-1392</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">39731014</article-id><article-id pub-id-type="pmc">PMC11681649</article-id><article-id pub-id-type="publisher-id">675</article-id><article-id pub-id-type="doi">10.1186/s11658-024-00675-6</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>ENPP2 promotes progression and lipid accumulation via AMPK/SREBP1/FAS pathway in chronic lymphocytic leukemia</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Lu</surname><given-names>Liyan</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Hu</surname><given-names>Xinting</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Han</surname><given-names>Yang</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Hua</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Tian</surname><given-names>Zheng</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Zhang</surname><given-names>Ya</given-names></name><address><email>maryzhangya@gmail.com</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Wang</surname><given-names>Xin</given-names></name><address><email>xinw007@126.com</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04983z422</institution-id><institution-id institution-id-type="GRID">grid.410638.8</institution-id><institution-id institution-id-type="ISNI">0000 0000 8910 6733</institution-id><institution>Department of Hematology, </institution><institution>Shandong Provincial Hospital Affiliated to Shandong First Medical University, </institution></institution-wrap>Add: No.324, Jingwu Road, Jinan, 250021 Shandong China </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/0207yh398</institution-id><institution-id institution-id-type="GRID">grid.27255.37</institution-id><institution-id institution-id-type="ISNI">0000 0004 1761 1174</institution-id><institution>Department of Hematology, Shandong Provincial Hospital, </institution><institution>Shandong University, </institution></institution-wrap>Jinan, 250021 Shandong China </aff><aff id="Aff3"><label>3</label>Taishan Scholars Program of Shandong Province, Jinan, 250021 Shandong China </aff></contrib-group><pub-date pub-type="epub"><day>27</day><month>12</month><year>2024</year></pub-date><pub-date pub-type="pmc-release"><day>27</day><month>12</month><year>2024</year></pub-date><pub-date pub-type="collection"><year>2024</year></pub-date><volume>29</volume><elocation-id>159</elocation-id><history><date date-type="received"><day>14</day><month>4</month><year>2024</year></date><date date-type="accepted"><day>3</day><month>12</month><year>2024</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2024</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article&#x02019;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#x02019;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p id="Par1">Disorders of lipid metabolism are critical factors in the progression of chronic lymphocytic leukemia (CLL). However, the characteristics of lipid metabolism and related regulatory mechanisms of CLL remain unclear.</p></sec><sec><title>Methods</title><p id="Par2">Hence, we identified altered metabolites and aberrant lipid metabolism pathways in patients with CLL by ultra-high-performance liquid chromatography-mass spectrometry-based non-targeted lipidomics. A combination of transcriptomics and lipidomics was used to mine relevant target molecule and downstream signaling pathway. In vitro cellular assays, quantitative real-time polymerase chain reaction (qRT-PCR), western blot, fluorescent staining, RNA sequencing, and coimmunoprecipitation were used to monitor the molecular levels as well as to explore the underlying mechanisms.</p></sec><sec><title>Results</title><p id="Par3">Significant differences in the content of 52 lipid species were identified in CLL samples and healthy controls. Functional analysis revealed that alterations in glycerolipid metabolism, glycerophospholipid metabolism, sphingolipid metabolism, and metabolic pathways had the greatest impact on CLL. On the basis of the area under the curve value, a combination of three metabolites (phosphatidylcholine O-24:2_18:2, phosphatidylcholine O-35:3, and lysophosphatidylcholine 34:3) potentially served as a biomarker for the diagnosis of CLL. Furthermore, utilizing integrated lipidomic, transcriptomic, and molecular studies, we reveal that ectonucleotide pyrophosphatase/phosphodiesterase 2 (ENPP2) plays a crucial role in regulating oncogenic lipogenesis. ENPP2 expression was significantly elevated in patients with CLL compared with normal cells and was validated in an independent cohort. Moreover, ENPP2 knockdown and targeted inhibitor PF-8380 treatment exerted an antitumor effect by regulating cell viability, proliferation, apoptosis, cell cycle, and enhanced the drug sensitivity to ibrutinib. Mechanistically, ENPP2 inhibited AMP-activated protein kinase (AMPK) phosphorylation and promoted lipogenesis through the sterol regulatory element-binding transcription factor 1 (SREBP-1)/fatty acid synthase (FAS) signaling pathway to promote lipogenesis.</p></sec><sec><title>Conclusions</title><p id="Par4">Taken together, our findings unravel the lipid metabolism characteristics of CLL. Moreover, we demonstrate a previously unidentified role and mechanism of ENPP2 in regulation of lipid metabolism, providing a novel therapeutic target for CLL treatment.</p></sec><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1186/s11658-024-00675-6.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Chronic lymphocytic leukemia</kwd><kwd>Lipidomics</kwd><kwd>Lipid metabolism</kwd><kwd>ENPP2</kwd><kwd>PF-8380</kwd><kwd>AMPK</kwd><kwd>LPL</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001809</institution-id><institution>National Natural Science Foundation of China</institution></institution-wrap></funding-source><award-id>82270200</award-id><award-id>82000195</award-id><award-id>82070203</award-id><award-id>81770210</award-id><principal-award-recipient><name><surname>Zhang</surname><given-names>Ya</given-names></name><name><surname>Wang</surname><given-names>Xin</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100002858</institution-id><institution>China Postdoctoral Science Foundation</institution></institution-wrap></funding-source><award-id>2022M721981</award-id><principal-award-recipient><name><surname>Zhang</surname><given-names>Ya</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100014103</institution-id><institution>Key Technology Research and Development Program of Shandong Province</institution></institution-wrap></funding-source><award-id>2018CXGC1213</award-id><principal-award-recipient><name><surname>Wang</surname><given-names>Xin</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution>Translational Research Grant of NCRCH</institution></funding-source><award-id>2020ZKMB01</award-id><award-id>2021WWB02</award-id><principal-award-recipient><name><surname>Wang</surname><given-names>Xin</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100010029</institution-id><institution>Taishan Scholar Foundation of Shandong Province</institution></institution-wrap></funding-source><award-id>tsqn201909184</award-id><award-id>tspd20230610</award-id><principal-award-recipient><name><surname>Zhang</surname><given-names>Ya</given-names></name><name><surname>Wang</surname><given-names>Xin</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100007129</institution-id><institution>Natural Science Foundation of Shandong Province</institution></institution-wrap></funding-source><award-id>ZR2020QH094</award-id><award-id>No. ZR2024MH050</award-id><award-id>ZR2020QH094</award-id><principal-award-recipient><name><surname>Zhang</surname><given-names>Ya</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution>Shandong Provincial Engineering Research Center of Lymphoma</institution></funding-source></award-group></funding-group><funding-group><award-group><funding-source><institution>Academic Promotion Programme of Shandong First Medical University</institution></funding-source><award-id>2019QL018</award-id><award-id>2020RC007</award-id><principal-award-recipient><name><surname>Zhang</surname><given-names>Ya</given-names></name><name><surname>Wang</surname><given-names>Xin</given-names></name></principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; University of Wroclav 2024</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par22">Chronic lymphocytic leukemia (CLL), a malignant B-cell tumor, is the most common form of adult leukemia in western countries [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]. As part of plastic and context-dependent metabolic reprogramming triggered by both oncogenic and environmental stimuli, cancer cells and other cell types use a variety of strategies to access lipids in the tumor microenvironment [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR4">4</xref>]. It has been observed that CLL cells could rapidly take up fatty acids to promote their proliferation [<xref ref-type="bibr" rid="CR5">5</xref>]. A close association between altered lipid metabolism and pathogenicity is supported. In this context, particular lipid profiles are evolving as distinct biomarkers with diagnostic capabilities. On the other hand, with the development of targeted therapeutic agents, there have been significant improvements in CLL treatment [<xref ref-type="bibr" rid="CR6">6</xref>&#x02013;<xref ref-type="bibr" rid="CR8">8</xref>], but CLL currently remains as a challenging hematologic neoplasm. Discovering innovative therapeutic targets for CLL remain significant imperatives that require attention.</p><p id="Par23">Ectonucleotide pyrophosphatase/phosphodiesterase 2 (ENPP2), an adipocyte-derived lysophospholipase D, played an extensive role in many metabolisms [<xref ref-type="bibr" rid="CR9">9</xref>&#x02013;<xref ref-type="bibr" rid="CR11">11</xref>]. ENPP2 expression is upregulated in corpulence patients and mice and is associated with insulin resistance and impaired glucose tolerance [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR12">12</xref>]. ENPP2 has been described to be engaged in several solid neoplasms, such as chondrosarcoma [<xref ref-type="bibr" rid="CR13">13</xref>], breast cancer [<xref ref-type="bibr" rid="CR14">14</xref>], hepatocellular carcinoma [<xref ref-type="bibr" rid="CR15">15</xref>], and pancreatic cancer [<xref ref-type="bibr" rid="CR16">16</xref>], and has been mentioned in multiple myeloma [<xref ref-type="bibr" rid="CR17">17</xref>]. Nevertheless, the effects of ENPP2 inhibition in CLL remain poorly understood.</p><p id="Par24">Herein, we integrated lipidomics and transcriptomics to investigate the lipid metabolic features of CLL. In addition, our study was the first investigation on the role of ENPP2 in the tumorigenesis of CLL. The biological processes involved were examined through loss-of-function and gain-of-function assays, and unraveling the regulatory mechanism in CLL. In conclusion, our results will inform a CLL treatment strategy.</p></sec><sec id="Sec2"><title>Materials and methods</title><sec id="Sec3"><title>Metabolomics data processing</title><p id="Par25">Data were analyzed as described previously [<xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR19">19</xref>]. Details of the methods is provided in the Supplementary Material. Fold change (FC)&#x02009;&#x0003e;&#x02009;2.0 or&#x02009;&#x0003c;&#x02009;0.5, q value&#x02009;&#x0003c;&#x02009;0.05 and variable importance in projection (VIP)&#x02009;&#x0003e;&#x02009;1 was taken as the screening conditions to obtain significantly different metabolites. By using LipidSearch 4.2, all differential feature ions were annotated. Using the R package (heatmap), a heatmap was created using the annotated differential lipids. On the basis of the Kyoto encyclopedia of genes and genomes (KEGG) database, a pathway enrichment study was done on LIPEA, and 25 enhanced pathways were displayed in a scatter plot. The area under the curve (AUC) was calculated and illustrated using GraphPad Prism 9.0.</p></sec><sec id="Sec4"><title>Transcriptome data analysis</title><p id="Par26">RNA extraction was performed on cell samples using RNAiso Plus from TaKaRa (Dalian, China). Subsequently, Huada Gene Technology Co. Ltd (Shenzhen, China) analyzed cell samples using the Illumina HiSeq 4000 platform. KEGG pathway analysis was performed on the screened differentially expressed genes (DEGs) to acquire the biological functions of these DEGs.</p></sec><sec id="Sec5"><title>Cell lines and reagents</title><p id="Par27">The MEC-1 cell line, a human p53 deleted/mutated CLL cell line, was obtained from the Moores Cancer Center at the University of California, San Diego. The human CLL cell line, EHEB, was derived from American Type Culture Collection (ATCC, Manassas, VA, USA). These cells were cultured in supplemented IMDM, RPMI-1640 medium with 10% heat-inactivated fetal bovine serum (FBS) obtained from Gibco, MD, USA, alongside 1% penicillin/streptomycin mixture, 2&#x000a0;mM L-glutamine, and incubated under ideal conditions of 37&#x000a0;&#x000b0;C with 5% CO<sub>2</sub>. Regular screening for mycoplasma infection was conducted on all cells. ENPP2 inhibitor PF-8380 (S8218, Selleck, Shanghai, China) and Ibrutinib (PCI-32765, MCE, Shanghai, China) were soluble in dimethyl sulfoxide (DMSO; Solarbio, Beijing, China).</p></sec><sec id="Sec6"><title>Patient specimens</title><p id="Par28">The medical ethics committee of Shandong Provincial Hospital approved this study and informed consent was acquired from each patient. The participants in this study were 82 patients diagnosed and treated in the department of hematology at Shandong Provincial Hospital, and their blood samples were collected. The criteria for diagnosing CLL were based on the revised International Workshop on Chronic Lymphocytic Leukemia (IWCLL) [<xref ref-type="bibr" rid="CR20">20</xref>]. Patients&#x02019; peripheral blood mononuclear cells (PBMCs) were extracted using the FicollHypaque density gradient method according to previously reported methods [<xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR22">22</xref>].</p></sec><sec id="Sec7"><title>RNA isolation and quantitative real-time PCR</title><p id="Par29">The purification of total RNA was carried out using RNAiso Plus (TaKaRa, Dalian, China). Reverse transcription was carried out utilizing a reverse transcription kit from the same source. In adherence to the manufacturer&#x02019;s instructions, quantitative real-time polymerase chain reaction (qRT-PCR) was conducted, and the results were analyzed through Light cycler 480 software. Primer sequences were as follows: ENPP2-F: ACTTGTGATGATAAGGTAGAGCCA; ENPP2-R: CTGTAGACCCTTTTGTATGAAGCC; LPL-F: AGTAGCAGAGTCCGTGGCTA; LPL-R: ATTCCTGTTACCGTCCAGCC; GAPDH-F: 5&#x02032;-GCACCGTCAAGGCTGAGAAC-3&#x02032;; GAPDH-R: 5&#x02032;-TGGTGAAGACGCCAGTGGA-3&#x02032;. Details of the methods is provided in the Supplementary Materials.</p></sec><sec id="Sec8"><title>Plasmid mediated regulation of ENPP2</title><p id="Par30">The sequences for ENPP2 shRNAS were as follows: shENPP2#1, 5&#x02032;-GCAGCAAAGTCATGCCTAATA-3&#x02032;; shENPP2#2, 5&#x02032;-GCAGTGCTTTATCGGACTAGA-3&#x02032;. The knockdown plasmids were synthesized by GenePharma (Shanghai, China). GenePharma (Shanghai, China) synthesized and purified corresponding negative control plasmids. The sequence of ENPP2 lvRNA was 5&#x02032;-CGCAAATGGGCGGTAGGCGTG-3&#x02032;. The pENTER-ENPP2-Flag/His plasmid was purchased from ViGene Biosciences Inc (Shandong, China). Lipofectamine 3000 reagent (Invitrogen) was used to transiently transfect plasmids into cells.</p></sec><sec id="Sec9"><title>Cell proliferation assays</title><p id="Par31">The procedure was performed as described previously [<xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR23">23</xref>]. Cell Counting Kit-8 (CCK-8) (Dojindo, Kumamoto, Japan) was used. Details of the methods is provided in the Supplementary Materials.</p></sec><sec id="Sec10"><title>Analysis of cell apoptosis and cell cycle</title><p id="Par32">The procedure was performed as described previously [<xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR23">23</xref>]. The reagents used were as follows: Annexin V-PE/7AAD Kit (BD Biosciences, Bedford, MA, USA); PI/RNase Staining Buffer (BD Biosciences, Bedford, MA, USA). Details of the methods is provided in the Supplementary Materials.</p></sec><sec id="Sec11"><title>Elisa assay</title><p id="Par33">Collect the cell supernatant after treating the cells separately and the concentration of lysophosphatidic acid (LPA) was measured using human LPA ELISA Kit (LANSO, China).</p></sec><sec id="Sec12"><title>Western blotting</title><p id="Par34">The western blot procedure was performed as described previously [<xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR23">23</xref>]. The primary antibodies used were as follows: ENPP2, LPL (Santa Cruz Biotechnology, USA), c-myc, Cyclin D1, CDK4, p21, p27, Bcl-2, Bax (Cell Signaling Technology, USA), AMPK, p-AMPK, SREBP1, FAS (abcam, USA), &#x003b1;-tubulin, and GAPDH (Zhongshan Goldenbridge, Beijing, China). Secondary antibodies were obtained from from Zhongshan Goldenbridge, Beijing, China. Details of the methods is provided in the Supplementary Materials.</p></sec><sec id="Sec13"><title>Triglyceride (TG) assay</title><p id="Par35">The quantification of TG content in CLL cells was performed in accordance with the instructions provided by the manufacturer. A triglyceride quantification kit (BC0625, Solarbio, China) was utilized for this purpose.</p></sec><sec id="Sec14"><title>Lipid staining assay</title><p id="Par36">Cells were incubated with BODIPY 493/503 (HY-W090090, MCE, USA) at 37&#x000a0;&#x000b0;C for 30&#x000a0;min in the incubator, with 4&#x02032;,6-diamidino-2-phenylindole (DAPI; Beyotime, Shanghai, China) for 5&#x000a0;min at room temperature and observed under a fluorescent microscope.</p></sec><sec id="Sec15"><title>Co-immunoprecipitation (Co-IP) assay</title><p id="Par37">Lysis of cells with Co-IP lysis solution. The resulting lysate was subjected to centrifugation, and the supernatant was treated with 1&#x02013;3 ug of primary antibody before being shaken and incubated at 4&#x000a0;&#x000b0;C overnight. Subsequently, Protein A/G agarose (Santa Cruz Biotechnology, USA) were added to the antibody-treated buffer and incubated for 1&#x000a0;h at 4&#x000a0;&#x000b0;C to facilitate antibody binding. Phosphate buffered saline (PBS) was used to wash the beads three times before heating at 100&#x000a0;&#x000b0;C to denature the proteins. Detection of target proteins was carried out using western blotting.</p></sec><sec id="Sec16"><title>Statistical analysis</title><p id="Par38">The data in this paper underwent statistical analysis using SPSS 26.0 software and GraphPad Prism 9.0 statistical software. The study presents the mean&#x02009;&#x000b1;&#x02009;standard deviation (SD) of results obtained from three distinct experiments. Student&#x02019;s <italic>t</italic>-test and Mann&#x02013;Whitney <italic>U</italic> test were used for direct comparisons, while multigroup comparisons were carried out using one-way analysis of variance (ANOVA) or two-way ANOVA. The significance threshold was established at *<italic> p</italic>&#x02009;&#x0003c;&#x02009;0.05 to declare statistical significance.</p></sec></sec><sec id="Sec17"><title>Results</title><sec id="Sec18"><title>Untargeted metabolomics demonstrate significant differences in lipid metabolites between patients with CLL and healthy controls</title><p id="Par39">To investigate the differences of lipid metabolites in patients with CLL and normal subjects, we retained patients with CLL blood supernatants for untargeted lipidomics profiling. Patient information and commonly associated indicators of clinical lipid metabolism are shown in Supplementary Table&#x000a0;1. In our study, we employed univariate analysis techniques, specifically assessing fold-change and utilizing <italic>t</italic>-test statistical testing with BH correction to derive q-values. Further, we integrated the VIP metric generated from multivariate statistical analysis, PLS-DA (Fig. S1A-C). The volcano plot (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>A) revealed a total of 913 differential feature ions, displaying apparent patterns of both upregulation and downregulation. Remarkable variations were observed in the levels of sphingolipids (SP), glycerolipids (GL), glycerophospholipids (GP), and fatty acids (FA) in patients afflicted with CLL, in comparison with their healthy counterparts. To illustrate the expression of the 52 annotated differential metabolites between CLL and healthy control groups, a clustering heatmap was utilized, as depicted in Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>B. To pinpoint the pathways with strong differential metabolite enrichment, we conducted a thorough analysis of the annotated results using enrichment analysis techniques. A comprehensive analysis has revealed the annotation of 52 differential metabolites, with 40 indicating an upregulation and 12 indicating a downregulation, as evidenced by Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>C. Metabolic analysis software MetaboAnalyst v5.0 was used to analyze 52 different metabolite pathways between patients with CLL and control samples, indicating significant enrichment of 24 pathways. The KEGG enrichment scatter plot <bold>(</bold>Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>D<bold>)</bold> shows that the metabolites differing between CLL patients and healthy controls were mainly labeled as enriched in glycerolipid metabolism, inositol phosphate metabolism, glycerophospholipid metabolism, ether lipid metabolism, sphingolipid metabolism, and metabolic pathways.<fig id="Fig1"><label>Fig.&#x000a0;1</label><caption><p>GC/LC&#x02013;MS based multivariate data analysis of serum data between CLL groups and healthy controls. <bold>A</bold> Differential metabolite volcano map. <bold>B</bold> Heat map clustering of serum metabolites from the case and healthy control groups according to liquid chromatography-mass spectrometry (LC&#x02013;MS). Significantly upregulated metabolites are shown in red (FC&#x02009;&#x02265;&#x02009;1, <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05), significantly downregulated metabolites are shown in blue (FC&#x02009;&#x02264;&#x02009;&#x02212;1, <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05), and non-significantly different metabolites are shown in gray. <bold>C</bold> Identification and annotation of metabolites. <bold>D</bold> Enrichment analysis of metabolites was performed. The scatter plot shows the most variable metabolic pathways. <bold>E</bold> receiver operating characteristic (ROC) curves of metabolic products</p></caption><graphic xlink:href="11658_2024_675_Fig1_HTML" id="MO1"/></fig></p><p id="Par40">Then, we conducted the comprehensive evaluation of the lipids to explore potential lipid biomarkers for diagnosing CLL. Through this investigation, five metabolites were discovered to have notable diagnostic significance, as evidenced by the top AUC values (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>E). Notably, all of the top five lipids exhibited AUC values above 0.93. Especially, PC O-24:2_18:2, which had the highest AUC value of 0.965 [95% confidence interval (CI) 0.9006&#x02013;1.000]. Three of these metabolites were chosen as combinational potential biomarkers for CLL. The model equation established after removing the confounding factor was Y&#x02009;=&#x02009;&#x02212;2.575&#x02009;+&#x02009;2.126*PC O-24:2_18:2&#x02009;+&#x02009;3.544*LPC 34:3&#x02009;+&#x02009;3.174* PC O-35:3. The area under the curve (AUC) value of these biomarkers was 0.92 (95% CI 0.764&#x02013;0.997), which was diagnostically significant.</p></sec><sec id="Sec19"><title>Integrative analysis of metabolomics and transcriptomics</title><p id="Par41">The genomic microarray profile GSE50006 was performed for transcriptome analysis. The DEGs screening threshold was set to |log2(fold change) |&#x0003e;&#x02009;0.25, adjusted to <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01. In this study, 539 DEGs were identified and 257 of the pathways were enriched, as depicted in Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>A, <xref rid="Fig2" ref-type="fig">B</xref>. In our current study, the pathway analysis based on metabolomics and transcriptomics data produced 20 KEGG pathways (Fig. S1D). As depicted in Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>C, these pathways cover a variety of metabolic processes, including phosphatidylinositol signaling system, phospholipase D signaling pathway, sphingolipid signaling pathway, choline metabolism in cancer, pathways in cancer, inositol phosphate metabolism, glycerophospholipid metabolism, glycerolipid metabolism, ether lipid metabolism, sphingolipid metabolism, fat digestion and absorption, and regulation of lipolysis in adipocytes. The details are shown in Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>.<fig id="Fig2"><label>Fig.&#x000a0;2</label><caption><p>Combined transcriptome and metabolome data analysis revealed abnormal expression of ENPP2 in CLL. <bold>A</bold> Sequencing data GSE50006 was downloaded from the GEO database with the screening condition |log2(fold change) |&#x0003e;&#x02009;2, <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001. Significantly up-regulated genes are shown in red, significantly down-regulated genes are shown in blue, and non-significantly different genes are shown in gray. <bold>B</bold> Enrichment analysis of differential genes was performed. <bold>C</bold> KEGG enrichment was performed on 20 genes. <bold>D</bold>, <bold>E</bold> ENPP2 expression was significantly upregulated in the CLL public database. The analysis was based on GSE5006 and GSE31048, respectively.<bold> F</bold> Overall survival (OS) curves of patients with CLL based on ENPP2 stratified expression of GSE22762. <bold>G</bold> ENPP2 mRNA was elevated in CLL progenitor cells compared with normal CD19<sup>+</sup> B cells. Data are shown as mean&#x02009;&#x000b1;&#x02009;SD. *<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05, **<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01, ***<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001, ****<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.0001</p></caption><graphic xlink:href="11658_2024_675_Fig2_HTML" id="MO2"/></fig><table-wrap id="Tab1"><label>Table&#x000a0;1</label><caption><p>Integrating metabolomics and transcriptomics for KEGG pathway enrichment and relevant genes</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Pathway</th><th align="left"><italic>p</italic>-Value</th><th align="left">Corrected <italic>p</italic>-value</th><th align="left">Gene symbol</th></tr></thead><tbody><tr><td align="left">Gap junction</td><td char="." align="char">0.038993</td><td char="." align="char">0.074212</td><td align="left">TUBB6|PDGFD|PRKACB</td></tr><tr><td align="left">Autophagy&#x02014;animal</td><td char="." align="char">0.00489</td><td char="." align="char"><bold>0.019897*</bold></td><td align="left">IGF1R|DDIT4|EIF2AK3|HIF1A|PRKACB</td></tr><tr><td align="left">Phosphatidylinositol signaling system</td><td char="." align="char">0.200611</td><td char="." align="char">0.255915</td><td align="left">PIK3C2B|DGKG</td></tr><tr><td align="left">Phospholipase D signaling pathway</td><td char="." align="char">0.008727</td><td char="." align="char"><bold>0.028197*</bold></td><td align="left">CYTH3|RAPGEF3|PDGFD|DGKG|IGH</td></tr><tr><td align="left">Sphingolipid signaling pathway</td><td char="." align="char">0.260831</td><td char="." align="char">0.315672</td><td align="left">S1PR5|TNFRSF1A</td></tr><tr><td align="left">Choline metabolism in cancer</td><td char="." align="char">0.001694</td><td char="." align="char"><bold>0.010158*</bold></td><td align="left"><bold>CHPT1|PDGFD|DGKG|HIF1A|FOS</bold></td></tr><tr><td align="left">Pathways in cancer</td><td char="." align="char">1.37E-05</td><td char="." align="char"><bold>0.000323**</bold></td><td align="left">CDKN2B|IGF1R|FOS|GNB4|PRKACB|RXRA|HIF1A|SMAD3|IL6|DLL1|JUP|ARAF|CDK6|IL15|LEF1|MYC</td></tr><tr><td align="left">Insulin resistance</td><td char="." align="char">0.063329</td><td char="." align="char">0.104514</td><td align="left">IL6|SOCS3|TNFRSF1A</td></tr><tr><td align="left">Pathogenic <italic>Escherichia coli</italic> infection</td><td char="." align="char">0.369197</td><td char="." align="char">0.410993</td><td align="left">TUBB6</td></tr><tr><td align="left">Inositol phosphate metabolism</td><td char="." align="char">0.460569</td><td char="." align="char">0.485242</td><td align="left">PIK3C2B</td></tr><tr><td align="left">Metabolic pathways</td><td char="." align="char">0.210821</td><td char="." align="char">0.263247</td><td align="left">PLD4|CD38|GCNT1|GPT2|AASS|NT5E|HACD1|PIK3C2B|MGAT3|RRM2|CHDH|CHPT1|LARGE1|DGKG|CSGALNACT1</td></tr><tr><td align="left">Glycerophospholipid metabolism</td><td char="." align="char">0.04923</td><td char="." align="char">0.086061</td><td align="left">PLD4|CHPT1|DGKG</td></tr><tr><td align="left">Glycerolipid metabolism</td><td char="." align="char">0.094317</td><td char="." align="char">0.147409</td><td align="left">MGAT3|DGKG</td></tr><tr><td align="left">Ether lipid metabolism</td><td char="." align="char">0.008024</td><td char="." align="char"><bold>0.027446*</bold></td><td align="left"><bold>PLD4|CHPT1|ENPP2</bold></td></tr><tr><td align="left">Sphingolipid metabolism</td><td char="." align="char">0.363591</td><td char="." align="char">0.415781</td><td align="left">SGPP2</td></tr><tr><td align="left">Fat digestion and absorption</td><td char="." align="char">0.048439</td><td char="." align="char">0.085311</td><td align="left">SCARB1|MGAT3</td></tr><tr><td align="left">Vitamin digestion and absorption</td><td char="." align="char">0.185855</td><td char="." align="char">0.240998</td><td align="left">SCARB1</td></tr><tr><td align="left">Regulation of lipolysis in adipocytes</td><td char="." align="char">0.369197</td><td char="." align="char">0.410993</td><td align="left">PRKACB</td></tr><tr><td align="left">Retrograde endocannabinoid signaling</td><td char="." align="char">0.036793</td><td char="." align="char">0.071173</td><td align="left">GNAO1|GABRB2|GNB4|PRKACB</td></tr><tr><td align="left">Long-term depression</td><td char="." align="char">0.015044</td><td char="." align="char"><bold>0.03859</bold></td><td align="left"><bold>GNAO1|IGF1R|ARAF</bold></td></tr></tbody></table><table-wrap-foot><p>The blod values means&#x000a0;statistically significant. *<italic>p</italic> &#x0003c; 0.05, **<italic>p</italic> &#x0003c; 0.01</p></table-wrap-foot></table-wrap></p><p id="Par42">By performing further analysis of the metabolism-related pathways on the basis of the corrected <italic>p</italic>-value, the choline metabolism pathway and the ether ester metabolism pathway were screened out. According to the transcriptome study refer to the two paths corresponding to the gene differences, namely cholinephosphotransferase-1 (CHPT1), platelet-derived growth factor-D (PDGFD), diacylglycerol kinase gamma (DGKG), hypoxia-inducible factor-1A (HIF-1A), FOS proto-oncogene (FOS), phospholipase D (PLD4), and ectonucleotide pyrophosphatase/phosphodiesterase2 (ENPP2). We preliminarily analyzed the differential expression of the above genes between patients with CLL and normal controls through public databases, and found that there were no significant differential features except for ENPP2 (Fig. S1E), and after reviewing literature, we chose to carry out the next step of research on the mechanism of action of the differential gene ENPP2 in CLL.</p></sec><sec id="Sec20"><title>Increased expression of ENPP2 in CLL cells</title><p id="Par43">In the gene databases GSE50006 and GSE31048, which include 376 patients with CLL, the data were normalized by extreme deviation, and the expression of ENPP2 was significantly higher than in normal group (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>D, <xref rid="Fig2" ref-type="fig">E</xref>). On the basis of statistical data from GSE22762, the Kaplan&#x02013;Meier method observed that exhibiting high levels of ENPP2 expression experienced a considerably diminished overall survival (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>F). Additionally, specimens from patients with CLL were selected for qRT-PCR analysis, which demonstrated that the expression level of ENPP2 in CLL specimens was significantly higher when compared with the normal group (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>G). Moreover, compared with B cells from healthy volunteers, ENPP2 messenger RNA (mRNA) expression in MEC-1 was significantly higher than that in B cells (Fig. S1F).</p></sec><sec id="Sec21"><title>RNA sequencing analysis for ENPP2 functional enrichment in CLL cells</title><p id="Par44">To investigate the attributes of ENPP2, RNA-sequencing was performed on MEC-1 cells transfected with both ShControl and ShENPP2#2. The results of our study, depicted in Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>A, indicate that ENPP2 was concentrated in pathways linked to metabolisms, such as the TCA cycle, ether lipid metabolism, and glycerophospholipid metabolism, through KEGG analysis. Gene ontology (GO) analysis revealed that ENPP2 is intimately involved in metabolic processes, cellular processes, and biological regulation (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>B). Gene set enrichment analysis (GSEA) revealed that ENPP2 was primary enriched in glycerolipid metabolism, triacylglycerol, and GTP diphosphate lyase (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>C&#x02013;E). Taken together, ENPP2 may promote the occurrence of CLL by regulating lipid metabolic pathways.<fig id="Fig3"><label>Fig.&#x000a0;3</label><caption><p>RNA-seq analysis of ENPP2 between ShControl and ShENPP2 cells. <bold>A</bold> KEGG enrichment analysis. <bold>B</bold> GO terms analysis of differently expressing genes. <bold>C</bold>&#x02013;<bold>E</bold> GSEA analysis of differential gene expression correlated with ENPP2 was performed. NES, normalized enrichment score</p></caption><graphic xlink:href="11658_2024_675_Fig3_HTML" id="MO3"/></fig></p></sec><sec id="Sec22"><title>ENPP2 regulates the proliferation, apoptosis, and cell cycle of CLL cells</title><p id="Par45">To confirm the results of our bioinformatics analysis, we conducted functional experiments in CLL cells to investigate the role of ENPP2. ENPP2 was successfully silenced by ShENPP2#1 and ShENPP2#2 in MEC-1 and EHEB cells (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>A), and verified the decreased expression of ENPP2 protein (Fig. S3A). We determined that downregulation of ENPP2 indirectly inhibited CLL cell proliferation through CCK-8 assays (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>B). Furthermore, through Annexin V-PE/7AAD assay, we observed a notable increase in apoptosis of shENPP2 transfected cells (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>C&#x02013;E). Additionally, we monitored the cell cycle of downregulated ENPP2 cells and found that they exhibited a significant G0/G1 phase block compared with control cells (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>F&#x02013;I). The results highlight that the ENPP2 contributes significantly to the survival of CLL cells through its ability to inhibit apoptosis and facilitate the progression of cells from the G0/G1 phase. To further verify the biological function of ENPP2, we constructed overexpressed plasmids (Fig. S2A). In contrast, ENPP2 overexpression promoted cell proliferation, reduced the proportion of apoptotic cells and accelerated the cell cycle (Fig. S2B&#x02013;D).<fig id="Fig4"><label>Fig.&#x000a0;4</label><caption><p>ENPP2 knockdown restrained the survival of CLL cell lines. <bold>A</bold> qRT-PCR assay for knockdown efficiency. <bold>B</bold> Proliferation curves of ENPP2 knockdown cells and control cells. <bold>C</bold>&#x02013;<bold>E</bold> Flow cytometry detection of apoptosis after ENPP2 knockdown. <bold>F</bold>&#x02013;<bold>I</bold> Flow cytometry detection of cycle distribution after ENPP2 knockdown and the relative proportions of cells in different cell cycle phases. Data are shown as mean&#x02009;&#x000b1;&#x02009;SD. *<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05, **<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01, ***<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001, ****<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.0001</p></caption><graphic xlink:href="11658_2024_675_Fig4_HTML" id="MO4"/></fig></p></sec><sec id="Sec23"><title>Targeted inhibition of ENPP2 by PF-8380 exerted anti-tumor activity in CLL cells</title><p id="Par46">ENPP2 inhibitor PF-8380 decreased proliferation of MEC-1 cells in dose-dependent and time-dependent manner (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>A). PF-8380 also impeded cell viability of CLL primary cells at micromolar concentration (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>B). In addition, ibrutinib supplementation with 16&#x000a0;&#x003bc;M or 4&#x000a0;&#x003bc;M PF-8380 increased cytotoxicity to CLL cells (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>C, <xref rid="Fig5" ref-type="fig">D</xref>). We used the combined index to determine the synergism of the two drugs. According to the judgment method of Soriano et al., 0.9&#x02009;&#x02264;&#x02009;combined index&#x02009;&#x02264;&#x02009;1.1 is superimposed, 0.8&#x02009;&#x02264;&#x02009;combined index&#x0003c;&#x02009;0.9 is low synergism, 0.6&#x02009;&#x02264;&#x02009;combined index&#x000a0;&#x0003c;&#x02009;0.8 is moderate synergism, 0.4&#x02009;&#x02264;&#x02009;combined index&#x02009;&#x0003c;&#x02009;0.6 is high synergism, and 0.2&#x02009;&#x02264;&#x02009;combined index&#x02009;&#x0003c;&#x02009;0.4 is strong synergism. We calculated a combined index of 0.74 in the MEC1 cell line and 0.45 in CLL#93 for the combination of ibrutinib and PF8380, which is sufficient to show that the two drugs are synergistic not only in the CLL cell line but also in primary cells.<fig id="Fig5"><label>Fig.&#x000a0;5</label><caption><p>Effect of ENPP2 target inhibitor PF-8380 in CLL cells. <bold>A</bold> CCK8 assay to detect the survival rate of CLL cell line MEC-1 treated with different concentrations of PF-8380. <bold>B</bold> CCK8 assay to detect the survival rate of CLL primary cells treated with different concentrations of PF-8380. <bold>C</bold> CCK8 assay to detect the survival rate of MEC-1 cells in combination with ibrutinib. <bold>D</bold> CCK8 assay to detect the cell survival rate of CLL primary cells treated with ibrutinib. <bold>E</bold>&#x02013;<bold>G</bold> Representative dot plots generated by flow cytometry analysis of PF-8380 groups versus negative control. <bold>H</bold>&#x02013;<bold>K</bold> Representative results for the cell cycle distributions with PF-8380. <bold>L</bold> Detection of cycle-associated protein expression levels in MEC-1 cells. <bold>M</bold>, <bold>N</bold> Detection of apoptosis-associated protein expression levels in MEC-1 cells. Data are shown as mean&#x02009;&#x000b1;&#x02009;SD of at least three independent experiments. *<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05, **<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01, ***<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001</p></caption><graphic xlink:href="11658_2024_675_Fig5_HTML" id="MO5"/></fig></p><p id="Par47">Moreover, the amount of apoptotic cells increased with the increase of PF-8380 concentration after 24&#x000a0;h flow cytometry analysis of MEC-1 and primary CLL cells treated with PF-8380 (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>E&#x02013;G). Compared with DMSO treatment, PF-8380 also induced the increase of G0/G1 phase cells (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>H&#x02013;K). Western blotting analysis showed that with the increase of PF-8380 concentration, the levels of cyclin-related proteins, including C-myc, Cyclin D1, CDK4, P21, and P27 (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>L) and apoptosis-related proteins, such as Bcl-2, Bax, and cle-PARP changed (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>M, <xref rid="Fig5" ref-type="fig">N</xref>). Taken together, PF-8380 exerts therapeutic potential by inhibiting CLL cell survival and cell cycle, enhancing apoptosis and chemosensitivity.</p></sec><sec id="Sec24"><title>ENPP2 regulates lipid metabolism in CLL</title><p id="Par48">Previous combined metabolomics and transcriptional analyses, as well as RNAseq, provide evidence that ENPP2 may act as a regulatory factor for lipid metabolism in CLL, and holds significance in the lipid metabolic process. To test this hypothesis, bodipy staining (Fig. S3C, D) showed increased lipid accumulation in ENPP2 overexpressed CLL cell lines and significantly reduced lipid accumulation in ENPP2 knockout cells. In addition, quantitative analysis of bodipy staining was performed by flow cytometry, and the results were consistent with the above (Fig. S4A&#x02013;D). We additionally validated this finding in CLL primary patients (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6</xref>A&#x02013;D).<fig id="Fig6"><label>Fig.&#x000a0;6</label><caption><p>Effect of ENPP2 knockdown and overexpression on intracellular lipids. Alterations of lipids in cells treated with PF-8380. <bold>A</bold>&#x02013;<bold>D</bold> Detection of primary patient cell lipid content by bodipy staining and flow cytometry. <bold>E</bold> Detection of intracellular lipid content of MEC-1 by Bodipy staining (lipids stained green and cell nuclei stained blue; scale bars, 100&#x000a0;&#x000b5;m). <bold>F</bold> Quantification of intracellular lipid content of MEC-1 by flow cytometry. <bold>G</bold> Detection of intracellular lipid content of EHEB by Bodipy staining (lipids stained green and cell nuclei stained blue; scale bars, 100&#x000a0;&#x000b5;m). <bold>H</bold> Quantification of intracellular lipid content of EHEB by flow cytometry. Data are shown as mean&#x02009;&#x000b1;&#x02009;SD of at least three independent experiments. *<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05, **<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01, ***<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001</p></caption><graphic xlink:href="11658_2024_675_Fig6_HTML" id="MO6"/></fig></p></sec><sec id="Sec25"><title>Effect of targeted inhibition PF-8380 on lipid metabolism in CLL cells</title><p id="Par49">To explore the effect of ENPP2-targeted drug PF-8380 on the lipid metabolism of CLL, we treated CLL cell lines with 16&#x000a0;&#x003bc;M and 32&#x000a0;&#x003bc;M, respectively. We stained them with bodipy (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6</xref>E, <xref rid="Fig6" ref-type="fig">G</xref>). The study findings suggest that as drug concentration increased, the intracellular lipid deposition decreased gradually. The quantitative treatment of bodipy staining by flow cytometry showed the same results as before (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6</xref>F, <xref rid="Fig6" ref-type="fig">H</xref>). Additionally, we measured the content of TG in the cells treated with the drug. The observed decline in TG content within the cells was found to be directly proportional to the increase in drug concentration (Fig. S3B). This trend is congruent with the results obtained via Bodipy staining. Taken together, the ENPP2 targeted inhibitor PF-8380 could alter the disease course by regulating lipid metabolism.</p></sec><sec id="Sec26"><title>ENPP2 functions through the AMPK/SREBP1/FAS pathway</title><p id="Par50">We then considered how ENPP2 regulates the process of lipogenesis in CLL. On the basis of RNA sequencing results, we became attracted to AMP-activated protein kinase (AMPK), which is a central player in metabolism[<xref ref-type="bibr" rid="CR24">24</xref>] and negatively correlates with tumor progression and genesis[<xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR26">26</xref>]. AMPK/SREBP1/FAS pathway is one of the key pathways for intracellular lipogenesis. AMPK regulates the expression of adipogenic genes through the sterol regulatory elements binding transcription factor 1(SREBP1) transcription factor. We examined the protein levels of p-AMPK, AMPK, SREBP1, and fatty acid synthase (FAS) to elucidate the molecular mechanism of ENPP2 involvement in cellular lipid metabolism. The results showed that the AMPK phosphorylated form was significantly increased in ENPP2 knockdown cells compared with control. Moreover, ENPP2 knockdown significantly decreased SREBP1 and FAS proteins. ENPP2 overexpression showed results corresponding to knockdown cells (Fig. S4E). We additionally validated this finding in patients with primary CLL (Fig.&#x000a0;<xref rid="Fig7" ref-type="fig">7</xref>A). In addition, we treated MEC-1 with 16&#x000a0;&#x003bc;M and 32&#x000a0;&#x003bc;M PF-8380, which showed enhanced AMPK phosphorylation and attenuated SREBP1 and FAS (Fig.&#x000a0;<xref rid="Fig7" ref-type="fig">7</xref>B). ENPP2 is a secreted lysophospholipase D that promotes the hydrolysis of extracellular lysophosphatidylcholine (LPC) to lysophosphatidic acid (LPA) [<xref ref-type="bibr" rid="CR27">27</xref>]. Therefore, we assayed the LPA content in cell supernatants after drug treatment utilizing ELISA. The results upon calibration for cell counts showed that both in the CLL cell line and primary cells from different patients with CLL, LPA in the cell supernatant was significantly decreased after treatment with the targeted inhibitor PF-8380 compared with the DMSO control (Fig.&#x000a0;<xref rid="Fig7" ref-type="fig">7</xref>C).<fig id="Fig7"><label>Fig.&#x000a0;7</label><caption><p>ENPP2 regulated AMPK signaling pathway and interacted with LPL. <bold>A</bold> Protein expression of p-AMPK, AMPK, SREBP1, and FAS in patient with primary CLL. <bold>B</bold> Protein expression of p-AMPK, AMPK, SREBP1, and FAS with PF-8380 treatment. <bold>C</bold> MEC-1, patients with CLL cells were treated with 32&#x000a0;&#x003bc;M PF8380 for 24&#x000a0;h and the cell supernatant LPA levels were measured by ELISA. <bold>D</bold> LPL was markedly upregulated in CLL public database. Analyses were on the basis of GSE31048. <bold>E</bold> Patients with CLL with unmutated IGHV presented high LPL expression (GSE69034). <bold>F</bold> Kaplan&#x02013;Meier survival curves of patients with CLL from GSE22762 with stratified LPL expression. <bold>G</bold>, <bold>H</bold> Correlation between ENPP2 and LPL mRNA expression in patients with CLL from GSE50006 and GSE31048. <bold>I</bold> qRT-PCR was performed to detect LPL mRNA content in ENPP2 knockdown and overexpression cells. <bold>J</bold> Western Blot assays for the amount of LPL protein in ENPP2 knockdown and overexpression cells. <bold>K</bold> Co-immunoprecipitation demonstrated that ENPP2 and LPL could be co-precipitated. Data are shown as mean&#x02009;&#x000b1;&#x02009;SD of at least three independent experiments, <italic>n</italic>&#x02009;=&#x02009;3. *<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05, **<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01, ***<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001</p></caption><graphic xlink:href="11658_2024_675_Fig7_HTML" id="MO7"/></fig></p></sec><sec id="Sec27"><title>ENPP2 interacted with LPL in CLL cells</title><p id="Par51">Lipoprotein lipase (LPL) has been identified as a crucial driver in the metabolic processes of CLL cells by facilitating the absorption of lipoprotein [<xref ref-type="bibr" rid="CR28">28</xref>&#x02013;<xref ref-type="bibr" rid="CR30">30</xref>]. The GSE31048, GSE69034, and GSE22762 normalized microarray RNA-seq data was download from the GEO database. We verified that LPL expression is increased in patients with CLL, and LPL expression was also significantly associated with unmutated IGHV genes (Fig.&#x000a0;<xref rid="Fig7" ref-type="fig">7</xref>D, <xref rid="Fig7" ref-type="fig">E</xref>). The results of Kaplan&#x02013;Meier survival curve analysis revealed a significant correlation between high LPL expression and poor prognosis in patients with CLL (Fig.&#x000a0;<xref rid="Fig7" ref-type="fig">7</xref>F). Meanwhile, in GEO database (GSE50006 and GSE31048), ENPP2 expression exhibited a significant positive correlation with LPL (Spearman: <italic>r</italic>&#x02009;=&#x02009;0.3057, <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.0001; Spearman: <italic>r</italic>&#x02009;=&#x02009;0.3653, <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.0001; Fig.&#x000a0;<xref rid="Fig7" ref-type="fig">7</xref>G&#x02013;H). It is hypothesized that ENPP2 may regulate CLL lipid metabolism through LPL. We transfected ShENPP2 and LvENPP2 into CLL cell lines to detect LPL levels. The results showed a significant positive correlation between LPL and ENPP2 expression, evident through analysis of mRNA and protein levels (F<xref rid="Fig7" ref-type="fig">i</xref>g.&#x000a0;<xref rid="Fig7" ref-type="fig">7</xref>I&#x02013;J). Subsequently, further Co-IP experiments revealed potential interactions between ENPP2 and LPL in CLL cells (Fig.&#x000a0;<xref rid="Fig7" ref-type="fig">7</xref>K). Our results provide evidence that ENPP2 modulates LPL expression in CLL. Taken together, the catalytic function of ENPP2 in CLL tumorigenesis was preliminarily elucidated (Fig.&#x000a0;<xref rid="Fig8" ref-type="fig">8</xref>).<fig id="Fig8"><label>Fig.&#x000a0;8</label><caption><p>Schematic model of ENPP2 mediated lipid metabolism</p></caption><graphic xlink:href="11658_2024_675_Fig8_HTML" id="MO8"/></fig></p></sec></sec><sec id="Sec28"><title>Discussion</title><p id="Par52">In this study, lipidomic analysis suggested differences in lipid metabolites between patients with CLL and age-matched healthy controls. The correlation between lipid metabolism and CLL has been substantiated. Considering that the age of onset of patients with chronic lymphocytic leukemia is commonly high, and lipid metabolism may change with increasing chronological age. Therefore, we performed a correlation analysis between patients&#x02019; age and common lipid metabolism indexes before analysis to exclude the interference of age. We used an untargeted quantitative metabolomics approach to examine and contrast the distinct serum metabolic profiles of patients with CLL and healthy individuals. We then validated the selected metabolites and corresponding pathways by transcriptomic data, thus identifying altered biological processes or metabolic features in patients with CLL. A total of 52 differential metabolites and 539 differential genes were defined, and three metabolites (PC O-24:2_18:2, PC O-35:3, LPC 34:3) were selected as biomarkers for CLL diagnosis on the basis of the ROC curve area.</p><p id="Par53">Additionally, further transcriptomic associations suggested that the CLL DEGs were significantly enriched in lipid metabolism pathways. On the basis of our analysis of CLL metabolomics combined with bioinformatics, we propose that ENPP2 might be closely related to the production of lipid metabolites and have important functions in lipid metabolism in CLL [<xref ref-type="bibr" rid="CR31">31</xref>&#x02013;<xref ref-type="bibr" rid="CR36">36</xref>]. ENPP2 has been documented to promote coronary atherosclerosis by mediating LDL production through the generation of LPA 20:4, 16:0, and 18:1 and by inducing CXCL1 expression [<xref ref-type="bibr" rid="CR31">31</xref>]. Our present study represents the role of ENPP2 in the pathogenesis of CLL, which is significantly expressed in patients with CLL, and predicted poorer survival and prognosis. Further, it was demonstrated that ENPP2 is involved in lipid metabolic pathways in CLL and promote cell survival by AMPK pathway to promote lipid deposition.</p><p id="Par54">Cancer cells require metabolic reorganization to improve their value-added and survival rates compared with normally differentiated cells. Previous studies have found that lipid metabolism is important in tumorigenesis, progression and metastasis. Disturbances in lipid metabolism may induce abnormal gene expression and lead to abnormal signaling pathways [<xref ref-type="bibr" rid="CR37">37</xref>]. Altered lipid metabolism is closely related to pathogenic processes and could give rise to distinct disease biomarkers with diagnostic, prognostic, and predictive capabilities. Untargeted metabolomics has emerged as an essential avenue for exploring lipid metabolism profiles [<xref ref-type="bibr" rid="CR38">38</xref>&#x02013;<xref ref-type="bibr" rid="CR42">42</xref>]. The investigation of the metabolic changes in CLL cells has revealed their ability to store lipids and derive chemical energy from free fatty acids, similar to adipocytes [<xref ref-type="bibr" rid="CR43">43</xref>]. Lipid droplet vesicles are present within the cytoplasm of CLL B cells, and upon incubation with free fatty acids, an upsurge in their metabolic rate could be witnessed [<xref ref-type="bibr" rid="CR29">29</xref>]. Pallasch&#x02019;s colleagues have identified significantly elevated levels of lipase-related genes and triglyceride-specific lipase activity in CLL B cells compared with normal CD5<sup>+</sup> B cells. Notably, the inhibition of lipase activity has been shown to increase CLL cell apoptosis [<xref ref-type="bibr" rid="CR44">44</xref>].</p><p id="Par55">ENPP2 as an adipose-derived secretory enzyme, controls adipose expansion, a fat brown supply and energy expenditure [<xref ref-type="bibr" rid="CR11">11</xref>]. In recent years, it has been shown that ENPP2 is closely correlated with obesity and disorders of glucolipid metabolism in obese individuals [<xref ref-type="bibr" rid="CR45">45</xref>]. It is considered a possible target for the treatment of obesity-related diseases. Adipocyte ENPP2 expression was accompanied by a substantial increase in adipogenesis in individuals exhibiting type II diabetes associated with obesity [<xref ref-type="bibr" rid="CR46">46</xref>]. Prior research has demonstrated the potential of ENPP2 as a prognostic biomarker in various cancers [<xref ref-type="bibr" rid="CR47">47</xref>], including breast and liver cancer [<xref ref-type="bibr" rid="CR48">48</xref>, <xref ref-type="bibr" rid="CR49">49</xref>]. Cholia and his colleagues found that ENPP2 enhances the aggressive potential of glioblastoma [<xref ref-type="bibr" rid="CR50">50</xref>]. Through a comprehensive analysis inclusive of RNA sequencing, this study sheds light on the regulatory role of ENPP2 in CLL. Furthermore, this investigation identified ENPP2 as an important biomarker of prognosis in CLL. Our analysis has revealed a dysregulated expression of ENPP2 in CLL, and a strong correlation between elevated ENPP2 expression and patient survival, as demonstrated in GSE22762, suggesting a potential role for ENPP2 in CLL progression. Further validation studies are required to confirm its predictive significance. Our findings indicate that the silencing of ENPP2 results in decreased cell proliferation, enhanced apoptosis, and G0/G1 cell cycle arrest.</p><p id="Par56">To elucidate the molecular mechanisms involved in lipid metabolism by ENPP2, we examined the degree of AMPK protein phosphorylation and downstream target gene regulation. AMPK is engaged in energy sensing and homeostasis regulation in vivo, and performs a crucial function in lipid regulation [<xref ref-type="bibr" rid="CR51">51</xref>]. AMPK is believed to be fundamental for lipid metabolism through the regulation of fatty acid synthesis and regulation [<xref ref-type="bibr" rid="CR52">52</xref>, <xref ref-type="bibr" rid="CR53">53</xref>]. Prior research has demonstrated that AMPK could modulate SREBP1 and FAS, thereby impacting adipogenesis and lipid metabolism [<xref ref-type="bibr" rid="CR24">24</xref>]. ENPP2 is more commonly reported for the formation and cellular function of its product LPA, which activates multiple signaling pathways, such as MEK/ERK, NF-kB, and CREB pathways, via G protein-coupled receptors [<xref ref-type="bibr" rid="CR36">36</xref>]. Coincidentally, LPA has been reported to stimulate glucose uptake and regulate AMPK phosphorylation. This connection may provide a novel insight into the regulation of lipid metabolism by ENPP2. Our research has demonstrated that the reduction of ENPP2 inhibits lipid accumulation by augmenting AMPK phosphorylation and reducing the level of SREBP1 and FAS. ENPP2 regulation of the AMPK/SREBP1/FAS signaling pathway may be an effective mechanism for anti-lipogenic effects in CLL cells.</p><p id="Par57">LPL is an enzyme normally expressed in adipocytes and muscle cells and is essential for the metabolism of free fatty acids [<xref ref-type="bibr" rid="CR54">54</xref>]. It has been demonstrated that it is not expressed in normal lymphocytes, but its expression is increased in CLL cells. It has also been meaningfully associated with the prognosis of CLL, and high expression levels of LPL are usually associated with poorer clinical outcomes [<xref ref-type="bibr" rid="CR55">55</xref>, <xref ref-type="bibr" rid="CR56">56</xref>]. LPL induces lipoprotein storage in CLL cells and reprograms CLL cells to preferentially use lipids as an energy source. It seems to result in a higher cell survival rate [<xref ref-type="bibr" rid="CR44">44</xref>, <xref ref-type="bibr" rid="CR54">54</xref>]. Metabolic reprogramming is initiated as CLL cells increase their demand for energy and metabolites to meet their rapid proliferation and survival [<xref ref-type="bibr" rid="CR2">2</xref>]. ENPP2 expression was increased in CLL cells. Consistent with our hypothesis, it has been observed that the downregulation of ENPP2 demonstrates notable anti-leukemic properties and reduced the role of key kinases in the lipid metabolism pathway. In CLL cells, LPL expression was reduced after ENPP2 silencing, whereas LPL expression was enhanced after ENPP2 overexpression, suggesting a positive effect of ENPP2 on LPL expression. We hypothesized that ENPP2 might participate in cellular lipid metabolism by binding to LPL, thus regulating CLL cell growth. Therefore, we elucidated the interaction between ENPP2 and LPL through Co-IP experiments. Our results demonstrate that the aberrant lipid metabolism pathway involved in ENPP2 is involved in the regulation of CLL onset and development.</p><p id="Par58">PF-8380 serves as a targeted inhibitor of ENPP2 and has been implicated in the pathogenesis and management of numerous diseases. Specifically, PF-8380 has been shown to elicit a reduction in tumor vascularity, delay tumor growth, and heighten radiosensitivity in glioblastoma [<xref ref-type="bibr" rid="CR57">57</xref>]. In a mouse model of hepatic encephalopathy, PF-8380 has demonstrated the ability to mitigate neuroinflammation and enhance neurological function [<xref ref-type="bibr" rid="CR58">58</xref>]. Studies undertaken by D&#x02019;Souza and colleagues have demonstrated that 24-h incubation of adipocytes with PF-8380 resulted in increased production of peroxisome proliferator-activated receptor &#x003b3; and downstream targets consequent to ENPP2 inhibition [<xref ref-type="bibr" rid="CR59">59</xref>]. Nevertheless, the role of PF-8380 in the treatment of CLL warrants further exploration. We have demonstrated the antitumor effect of PF-8380 in CLL through in vitro experimentation, which confers a novel avenue for the treatment of this malignancy.</p><p id="Par59">Over the past few years, targeted drug therapies have demonstrated remarkable therapeutic effects in CLL [<xref ref-type="bibr" rid="CR60">60</xref>]. Although ibrutinib, a Bruton&#x02019;s tyrosine kinase inhibitor, has displayed impressive efficacy in CLL treatment [<xref ref-type="bibr" rid="CR61">61</xref>], its clinical resistance is still a significant challenge. Drug resistance and toxicity lead to poor clinical outcomes [<xref ref-type="bibr" rid="CR62">62</xref>&#x02013;<xref ref-type="bibr" rid="CR64">64</xref>], which could be mitigated through the implementation of combination therapy aimed at reducing the incidence of drug resistance [<xref ref-type="bibr" rid="CR65">65</xref>]. In our study, we observed that the ENPP2 targeted inhibitor PF-8380 exhibited positive antidrug resistance in CLL-targeted drug sensitivities, such as Ibrutinib, thus providing new prospects for clinical chemotherapy resistance. However, it is imperative to further investigate the mechanism of resistance and the clinical implementation of PF-8380 in the treatment of CLL.</p></sec><sec id="Sec29"><title>Conclusions</title><p id="Par60">In summary, our investigation has screened differential metabolites of CLL and established a diagnostic model utilizing lipidomic. Furthermore, our results have highlighted the potential of inhibiting ENPP2 to impede the progression of CLL. Specifically, we have observed antitumor effects of PF-8380 in CLL, such as hindering cell survival, enhancing cell apoptosis, and blocking the cell cycle. Taken together, our findings suggest that ENPP2 serves as a promising target for targeted therapeutic interventions, potentially paving the way for an innovative approach to treating CLL.</p></sec><sec id="Sec30" sec-type="supplementary-material"><title>Supplementary Information</title><p>
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="11658_2024_675_MOESM1_ESM.docx"><caption><p>Additional file 1.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM2"><media xlink:href="11658_2024_675_MOESM2_ESM.jpg"><caption><p>Additional file 2. Supplementary Fig&#x000a0;S1. <bold>A</bold> LC-MS based PCA score plot. <bold>B</bold> PLS-DA score plot (R2&#x02009;=&#x02009;0.935, Q2&#x02009;=&#x02009;0.679). <bold>C</bold> PLS-DA model alignment test. Two coordinate points on the scoring plot are relatively far apart, indicating a significant difference between the two samples, and vice versa. The oval area represents the 95% confidence interval. <bold>D</bold> Higher expression of ENPP2 mRNA in CLL cell line MEC-1 than in normal CD19<sup>+</sup> B cells was detected by qRT-PCR. <bold>E</bold> Venn diagram showing metabolomics and transcriptomics with 20 intersecting genes. <bold>F</bold> All integrated DEGs were analyzed for protein-protein interaction networks using the STRING database.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM3"><media xlink:href="11658_2024_675_MOESM3_ESM.jpg"><caption><p>Additional file 3. Supplementary Fig.&#x000a0;S2. <bold>A</bold> qRT-PCR detection of ENPP2 overexpression efficiency. <bold>B</bold> Proliferation curves of ENPP2 overexpression and control cells. <bold>C</bold>&#x02013;<bold>E</bold> Flow cytometry detection of apoptosis after ENPP2 overexpression. <bold>F</bold> Flow cytometry detection of cycle distribution after ENPP2 overexpression and the relative proportions of cells in different cell cycle phases. Data were shown as the mean&#x02009;&#x000b1;&#x02009;SD of at least three independent experiments. *<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05, **<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01, ***<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM4"><media xlink:href="11658_2024_675_MOESM4_ESM.jpg"><caption><p>Additional file 4. Supplementary Fig.&#x000a0;S3. <bold>A</bold> Protein expression following knockdown of ENPP2. <bold>B</bold> Detection of intracellular triglyceride content. <bold>C</bold>, <bold>D</bold> Quantification of MEC-1 and EHEB intracellular lipid content by bodipy staining (lipids stained green and cell nuclei stained blue; scale bars, 100&#x000a0;&#x000b5;m). Data were shown as the mean&#x02009;&#x000b1;&#x02009;SD of at least three independent experiments. *<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05, **<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01, ***<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM5"><media xlink:href="11658_2024_675_MOESM5_ESM.jpg"><caption><p>Additional file 5. Supplementary Fig.&#x000a0;S4.<bold> A</bold>&#x02013;<bold>D</bold> Detection of MEC-1 and EHEB lipid content by bodipy staining and flow cytometry (lipids stained green and cell nuclei stained blue; scale bars, 100&#x000a0;&#x000b5;m). <bold>E</bold> Protein expression of ENPP2, p-AMPK, AMPK, SREBP1, FAS in CLL cells.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM6"><media xlink:href="11658_2024_675_MOESM6_ESM.jpg"><caption><p>Additional file 6. Supplementary Fig.&#x000a0;S5. <bold>A</bold> The quantitative data of cycle-associated protein expression levels in MEC-1 cells. <bold>B</bold> The quantitative data of apoptosis-associated protein expression levels in MEC-1 cells. <bold>C</bold> The quantitative data of p-AMPK, AMPK, SREBP1, FAS in primary CLL patient. <bold>D</bold> The quantitative data of p-AMPK, AMPK, SREBP1, FAS with PF-8380 treatment. Data were shown as the mean&#x02009;&#x000b1;&#x02009;SD of at least three independent experiments, n&#x02009;=&#x02009;3. *<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05, **<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01, ***<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM7"><media xlink:href="11658_2024_675_MOESM7_ESM.docx"><caption><p>Additional file 7. Supplementary Table&#x000a0;S1. Clinical information for CLL patients.</p></caption></media></supplementary-material></p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>CLL</term><def><p id="Par5">Chronic lymphocytic leukemia</p></def></def-item><def-item><term>ENPP2</term><def><p id="Par6">Ectonucleotide pyrophosphatase/phosphodiesterase 2</p></def></def-item><def-item><term>LPL</term><def><p id="Par7">Lipoprotein lipase</p></def></def-item><def-item><term>AMPK</term><def><p id="Par8">Adenosine 5&#x02032;-monophosphate (AMP)-activated protein kinase</p></def></def-item><def-item><term>SREBP1</term><def><p id="Par9">Sterol regulatory element-binding protein 1</p></def></def-item><def-item><term>FAS</term><def><p id="Par10">Fatty acid synthase</p></def></def-item><def-item><term>IWCLL</term><def><p id="Par11">International workshop on chronic lymphocytic leukemia</p></def></def-item><def-item><term>PBMCs</term><def><p id="Par12">Peripheral blood mononuclear cells</p></def></def-item><def-item><term>OS</term><def><p id="Par13">Overall survival</p></def></def-item><def-item><term>RNA-seq</term><def><p id="Par14">RNA sequencing</p></def></def-item><def-item><term>GEO</term><def><p id="Par15">Gene Expression Omnibus</p></def></def-item><def-item><term>KEGG</term><def><p id="Par16">Kyoto Encyclopedia of Genes and Genomes</p></def></def-item><def-item><term>GO</term><def><p id="Par17">Gene Ontology</p></def></def-item><def-item><term>qRT-PCR</term><def><p id="Par18">Quantitative real-time polymerase chain reaction</p></def></def-item><def-item><term>MOI</term><def><p id="Par19">Multiplicity of infection</p></def></def-item><def-item><term>CCK8</term><def><p id="Par20">Cell Counting Kit-8</p></def></def-item><def-item><term>Co-IP</term><def><p id="Par21">Co-Immunoprecipitation</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Publisher&#x02019;s Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><ack><title>Acknowledgements</title><p>We appreciate TCGA database and GEO database for offering their platforms and contributors for uploading their significant data.</p></ack><notes notes-type="author-contribution"><title>Author contributions</title><p>X.W. and Y.Z. were responsible for the direction and supervision of this research and for revising the manuscript; L.L. conducted the experiments and wrote the manuscript; X.H. and Y.H. collected the data; H.W. and Z.T. performed the statistical analyses. All authors read and approved the final manuscript.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>This study was funded by National Natural Science Foundation (no. 82270200, no. 82000195, no. 82070203, and no. 81770210); China Postdoctoral Science Foundation (no. 2022M721981); Taishan Scholars Program of Shandong Province; Shandong Provincial Engineering Research Center of Lymphoma; Key Research and Development Program of Shandong Province (no. 2018CXGC1213); Academic Promotion Programme of Shandong First Medical University (no. 2019QL018); Translational Research Grant of NCRCH (no. 2021WWB02, no. 2020ZKMB01); and Shandong Provincial Natural Science Foundation (no. ZR2024MH050, ZR2020QH094); Shandong Provincial Health Construction Program of Medical Science and Technology Innovation Team; Research Promotion Program of Shandong Provincial Hospital.</p></notes><notes notes-type="data-availability"><title>Availability of data and materials</title><p>The datasets used and/or analyzed in our study are available from the GEO database (<ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/geo/">https://www.ncbi.nlm.nih.gov/geo/</ext-link>) and the TCGA database (<ext-link ext-link-type="uri" xlink:href="https://portal.gdc.cancer.gov/">https://portal.gdc.cancer.gov/</ext-link>). The original images of western blotting analysis in this study are included in Additional file. The additional data supporting the findings of this study could be obtained from the corresponding author upon reasonable request.</p></notes><notes><title>Declarations</title><notes id="FPar1"><title>Ethics approval and consent to participate</title><p id="Par61">This study using human tissues was approved by Shandong Provincial Hospital&#x02019;s medical ethical committee (approval no. 2021-217, date: 1 March 2021). Informed consent was obtained for the collection of all samples in accordance with the Declaration of Helsinki.</p></notes><notes id="FPar2"><title>Consent for publication</title><p id="Par62">Not applicable.</p></notes><notes id="FPar3" notes-type="COI-statement"><title>Competing interests</title><p id="Par63">The authors declare that they have no competing interests.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name><surname>Scarfo</surname><given-names>L</given-names></name><name><surname>Ferreri</surname><given-names>AJ</given-names></name><name><surname>Ghia</surname><given-names>P</given-names></name></person-group><article-title>Chronic lymphocytic leukaemia</article-title><source>Crit Rev Oncol Hematol</source><year>2016</year><volume>104</volume><fpage>169</fpage><lpage>182</lpage><pub-id pub-id-type="doi">10.1016/j.critrevonc.2016.06.003</pub-id><pub-id pub-id-type="pmid">27370174</pub-id>
</element-citation><mixed-citation id="mc-CR1" publication-type="journal">Scarfo L, Ferreri AJ, Ghia P. Chronic lymphocytic leukaemia. Crit Rev Oncol Hematol. 2016;104:169&#x02013;82.<pub-id pub-id-type="pmid">27370174</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name><surname>Nie</surname><given-names>Y</given-names></name><name><surname>Yun</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name></person-group><article-title>Targeting metabolic reprogramming in chronic lymphocytic leukemia</article-title><source>Exp Hematol Oncol</source><year>2022</year><volume>11</volume><issue>1</issue><fpage>39</fpage><pub-id pub-id-type="doi">10.1186/s40164-022-00292-z</pub-id><pub-id pub-id-type="pmid">35761419</pub-id>
</element-citation><mixed-citation id="mc-CR2" publication-type="journal">Nie Y, Yun X, Zhang Y, Wang X. Targeting metabolic reprogramming in chronic lymphocytic leukemia. Exp Hematol Oncol. 2022;11(1):39.<pub-id pub-id-type="pmid">35761419</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name><surname>Currie</surname><given-names>E</given-names></name><name><surname>Schulze</surname><given-names>A</given-names></name><name><surname>Zechner</surname><given-names>R</given-names></name><name><surname>Walther</surname><given-names>TC</given-names></name><name><surname>Farese</surname><given-names>RV</given-names><suffix>Jr</suffix></name></person-group><article-title>Cellular fatty acid metabolism and cancer</article-title><source>Cell Metab</source><year>2013</year><volume>18</volume><issue>2</issue><fpage>153</fpage><lpage>161</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2013.05.017</pub-id><pub-id pub-id-type="pmid">23791484</pub-id>
</element-citation><mixed-citation id="mc-CR3" publication-type="journal">Currie E, Schulze A, Zechner R, Walther TC, Farese RV Jr. Cellular fatty acid metabolism and cancer. Cell Metab. 2013;18(2):153&#x02013;61.<pub-id pub-id-type="pmid">23791484</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name><surname>Martin-Perez</surname><given-names>M</given-names></name><name><surname>Urdiroz-Urricelqui</surname><given-names>U</given-names></name><name><surname>Bigas</surname><given-names>C</given-names></name><name><surname>Benitah</surname><given-names>SA</given-names></name></person-group><article-title>The role of lipids in cancer progression and metastasis</article-title><source>Cell Metab</source><year>2022</year><volume>34</volume><issue>11</issue><fpage>1675</fpage><lpage>1699</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2022.09.023</pub-id><pub-id pub-id-type="pmid">36261043</pub-id>
</element-citation><mixed-citation id="mc-CR4" publication-type="journal">Martin-Perez M, Urdiroz-Urricelqui U, Bigas C, Benitah SA. The role of lipids in cancer progression and metastasis. Cell Metab. 2022;34(11):1675&#x02013;99.<pub-id pub-id-type="pmid">36261043</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name><surname>Thurgood</surname><given-names>LA</given-names></name><name><surname>Best</surname><given-names>OG</given-names></name><name><surname>Rowland</surname><given-names>A</given-names></name><name><surname>Lower</surname><given-names>KM</given-names></name><name><surname>Brooks</surname><given-names>DA</given-names></name><name><surname>Kuss</surname><given-names>BJ</given-names></name></person-group><article-title>Lipid uptake in chronic lymphocytic leukemia</article-title><source>Exp Hematol</source><year>2022</year><volume>106</volume><fpage>58</fpage><lpage>67</lpage><pub-id pub-id-type="doi">10.1016/j.exphem.2021.12.193</pub-id><pub-id pub-id-type="pmid">34896245</pub-id>
</element-citation><mixed-citation id="mc-CR5" publication-type="journal">Thurgood LA, Best OG, Rowland A, Lower KM, Brooks DA, Kuss BJ. Lipid uptake in chronic lymphocytic leukemia. Exp Hematol. 2022;106:58&#x02013;67.<pub-id pub-id-type="pmid">34896245</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name><surname>Smolewski</surname><given-names>P</given-names></name><name><surname>Robak</surname><given-names>T</given-names></name></person-group><article-title>Current treatment of refractory/relapsed chronic lymphocytic leukemia: a focus on novel drugs</article-title><source>Acta Haematol</source><year>2021</year><volume>144</volume><issue>4</issue><fpage>365</fpage><lpage>379</lpage><pub-id pub-id-type="doi">10.1159/000510768</pub-id><pub-id pub-id-type="pmid">33238270</pub-id>
</element-citation><mixed-citation id="mc-CR6" publication-type="journal">Smolewski P, Robak T. Current treatment of refractory/relapsed chronic lymphocytic leukemia: a focus on novel drugs. Acta Haematol. 2021;144(4):365&#x02013;79.<pub-id pub-id-type="pmid">33238270</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Lu</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Miao</surname><given-names>Y</given-names></name></person-group><article-title>Combining BTK inhibitors with BCL2 inhibitors for treating chronic lymphocytic leukemia and mantle cell lymphoma</article-title><source>Biomark Res</source><year>2022</year><volume>10</volume><issue>1</issue><fpage>17</fpage><pub-id pub-id-type="doi">10.1186/s40364-022-00357-5</pub-id><pub-id pub-id-type="pmid">35379357</pub-id>
</element-citation><mixed-citation id="mc-CR7" publication-type="journal">Zhang J, Lu X, Li J, Miao Y. Combining BTK inhibitors with BCL2 inhibitors for treating chronic lymphocytic leukemia and mantle cell lymphoma. Biomark Res. 2022;10(1):17.<pub-id pub-id-type="pmid">35379357</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name><surname>Nguyen</surname><given-names>PH</given-names></name><name><surname>Niesen</surname><given-names>E</given-names></name><name><surname>Hallek</surname><given-names>M</given-names></name></person-group><article-title>New roles for B cell receptor associated kinases: when the B cell is not the target</article-title><source>Leukemia</source><year>2019</year><volume>33</volume><issue>3</issue><fpage>576</fpage><lpage>587</lpage><pub-id pub-id-type="doi">10.1038/s41375-018-0366-8</pub-id><pub-id pub-id-type="pmid">30700840</pub-id>
</element-citation><mixed-citation id="mc-CR8" publication-type="journal">Nguyen PH, Niesen E, Hallek M. New roles for B cell receptor associated kinases: when the B cell is not the target. Leukemia. 2019;33(3):576&#x02013;87.<pub-id pub-id-type="pmid">30700840</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name><surname>Koike</surname><given-names>S</given-names></name><name><surname>Keino-Masu</surname><given-names>K</given-names></name><name><surname>Ohto</surname><given-names>T</given-names></name><name><surname>Masu</surname><given-names>M</given-names></name></person-group><article-title>The N-terminal hydrophobic sequence of autotaxin (ENPP2) functions as a signal peptide</article-title><source>Genes Cells</source><year>2006</year><volume>11</volume><issue>2</issue><fpage>133</fpage><lpage>142</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2443.2006.00924.x</pub-id><pub-id pub-id-type="pmid">16436050</pub-id>
</element-citation><mixed-citation id="mc-CR9" publication-type="journal">Koike S, Keino-Masu K, Ohto T, Masu M. The N-terminal hydrophobic sequence of autotaxin (ENPP2) functions as a signal peptide. Genes Cells. 2006;11(2):133&#x02013;42.<pub-id pub-id-type="pmid">16436050</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name><surname>Nishimasu</surname><given-names>H</given-names></name><name><surname>Ishitani</surname><given-names>R</given-names></name><name><surname>Aoki</surname><given-names>J</given-names></name><name><surname>Nureki</surname><given-names>O</given-names></name></person-group><article-title>A 3D view of autotaxin</article-title><source>Trends Pharmacol Sci</source><year>2012</year><volume>33</volume><issue>3</issue><fpage>138</fpage><lpage>145</lpage><pub-id pub-id-type="doi">10.1016/j.tips.2011.12.004</pub-id><pub-id pub-id-type="pmid">22277299</pub-id>
</element-citation><mixed-citation id="mc-CR10" publication-type="journal">Nishimasu H, Ishitani R, Aoki J, Nureki O. A 3D view of autotaxin. Trends Pharmacol Sci. 2012;33(3):138&#x02013;45.<pub-id pub-id-type="pmid">22277299</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name><surname>Reeves</surname><given-names>VL</given-names></name><name><surname>Trybula</surname><given-names>JS</given-names></name><name><surname>Wills</surname><given-names>RC</given-names></name><name><surname>Goodpaster</surname><given-names>BH</given-names></name><name><surname>Dube</surname><given-names>JJ</given-names></name><name><surname>Kienesberger</surname><given-names>PC</given-names></name><etal/></person-group><article-title>Serum Autotaxin/ENPP2 correlates with insulin resistance in older humans with obesity</article-title><source>Obesity (Silver Spring)</source><year>2015</year><volume>23</volume><issue>12</issue><fpage>2371</fpage><lpage>2376</lpage><pub-id pub-id-type="doi">10.1002/oby.21232</pub-id><pub-id pub-id-type="pmid">26727116</pub-id>
</element-citation><mixed-citation id="mc-CR11" publication-type="journal">Reeves VL, Trybula JS, Wills RC, Goodpaster BH, Dube JJ, Kienesberger PC, et al. Serum Autotaxin/ENPP2 correlates with insulin resistance in older humans with obesity. Obesity (Silver Spring). 2015;23(12):2371&#x02013;6.<pub-id pub-id-type="pmid">26727116</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name><surname>Rancoule</surname><given-names>C</given-names></name><name><surname>Dusaulcy</surname><given-names>R</given-names></name><name><surname>Treguer</surname><given-names>K</given-names></name><name><surname>Gres</surname><given-names>S</given-names></name><name><surname>Attane</surname><given-names>C</given-names></name><name><surname>Saulnier-Blache</surname><given-names>JS</given-names></name></person-group><article-title>Involvement of autotaxin/lysophosphatidic acid signaling in obesity and impaired glucose homeostasis</article-title><source>Biochimie</source><year>2014</year><volume>96</volume><fpage>140</fpage><lpage>143</lpage><pub-id pub-id-type="doi">10.1016/j.biochi.2013.04.010</pub-id><pub-id pub-id-type="pmid">23639740</pub-id>
</element-citation><mixed-citation id="mc-CR12" publication-type="journal">Rancoule C, Dusaulcy R, Treguer K, Gres S, Attane C, Saulnier-Blache JS. Involvement of autotaxin/lysophosphatidic acid signaling in obesity and impaired glucose homeostasis. Biochimie. 2014;96:140&#x02013;3.<pub-id pub-id-type="pmid">23639740</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name><surname>Sioletic</surname><given-names>S</given-names></name><name><surname>Czaplinski</surname><given-names>J</given-names></name><name><surname>Hu</surname><given-names>L</given-names></name><name><surname>Fletcher</surname><given-names>JA</given-names></name><name><surname>Fletcher</surname><given-names>CD</given-names></name><name><surname>Wagner</surname><given-names>AJ</given-names></name><etal/></person-group><article-title>c-Jun promotes cell migration and drives expression of the motility factor ENPP2 in soft tissue sarcomas</article-title><source>J Pathol</source><year>2014</year><volume>234</volume><issue>2</issue><fpage>190</fpage><lpage>202</lpage><pub-id pub-id-type="doi">10.1002/path.4379</pub-id><pub-id pub-id-type="pmid">24852265</pub-id>
</element-citation><mixed-citation id="mc-CR13" publication-type="journal">Sioletic S, Czaplinski J, Hu L, Fletcher JA, Fletcher CD, Wagner AJ, et al. c-Jun promotes cell migration and drives expression of the motility factor ENPP2 in soft tissue sarcomas. J Pathol. 2014;234(2):190&#x02013;202.<pub-id pub-id-type="pmid">24852265</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name><surname>Drosouni</surname><given-names>A</given-names></name><name><surname>Panagopoulou</surname><given-names>M</given-names></name><name><surname>Aidinis</surname><given-names>V</given-names></name><name><surname>Chatzaki</surname><given-names>E</given-names></name></person-group><article-title>Autotaxin in breast cancer: role, epigenetic regulation and clinical implications</article-title><source>Cancers (Basel).</source><year>2022</year><volume>14</volume><issue>21</issue><fpage>5437</fpage><pub-id pub-id-type="doi">10.3390/cancers14215437</pub-id><pub-id pub-id-type="pmid">36358855</pub-id>
</element-citation><mixed-citation id="mc-CR14" publication-type="journal">Drosouni A, Panagopoulou M, Aidinis V, Chatzaki E. Autotaxin in breast cancer: role, epigenetic regulation and clinical implications. Cancers (Basel). 2022;14(21):5437.<pub-id pub-id-type="pmid">36358855</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name><surname>Kaffe</surname><given-names>E</given-names></name><name><surname>Magkrioti</surname><given-names>C</given-names></name><name><surname>Aidinis</surname><given-names>V</given-names></name></person-group><article-title>Deregulated lysophosphatidic acid metabolism and signaling in liver cancer</article-title><source>Cancers (Basel).</source><year>2019</year><volume>11</volume><issue>11</issue><fpage>1626</fpage><pub-id pub-id-type="doi">10.3390/cancers11111626</pub-id><pub-id pub-id-type="pmid">31652837</pub-id>
</element-citation><mixed-citation id="mc-CR15" publication-type="journal">Kaffe E, Magkrioti C, Aidinis V. Deregulated lysophosphatidic acid metabolism and signaling in liver cancer. Cancers (Basel). 2019;11(11):1626.<pub-id pub-id-type="pmid">31652837</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name><surname>Quan</surname><given-names>M</given-names></name><name><surname>Cui</surname><given-names>JJ</given-names></name><name><surname>Feng</surname><given-names>X</given-names></name><name><surname>Huang</surname><given-names>Q</given-names></name></person-group><article-title>The critical role and potential target of the autotaxin/lysophosphatidate axis in pancreatic cancer</article-title><source>Tumour Biol</source><year>2017</year><volume>39</volume><issue>3</issue><fpage>1010428317694544</fpage><pub-id pub-id-type="doi">10.1177/1010428317694544</pub-id><pub-id pub-id-type="pmid">28347252</pub-id>
</element-citation><mixed-citation id="mc-CR16" publication-type="journal">Quan M, Cui JJ, Feng X, Huang Q. The critical role and potential target of the autotaxin/lysophosphatidate axis in pancreatic cancer. Tumour Biol. 2017;39(3):1010428317694544.<pub-id pub-id-type="pmid">28347252</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Xu</surname><given-names>T</given-names></name><name><surname>Zhao</surname><given-names>X</given-names></name><name><surname>Jiang</surname><given-names>X</given-names></name><name><surname>Xiao</surname><given-names>F</given-names></name><etal/></person-group><article-title>Aberrant ENPP2 expression promotes tumor progression in multiple myeloma</article-title><source>Leuk Lymphoma</source><year>2022</year><volume>63</volume><issue>4</issue><fpage>963</fpage><lpage>974</lpage><pub-id pub-id-type="doi">10.1080/10428194.2021.2010055</pub-id><pub-id pub-id-type="pmid">34847837</pub-id>
</element-citation><mixed-citation id="mc-CR17" publication-type="journal">Li Y, Zhang L, Xu T, Zhao X, Jiang X, Xiao F, et al. Aberrant ENPP2 expression promotes tumor progression in multiple myeloma. Leuk Lymphoma. 2022;63(4):963&#x02013;74.<pub-id pub-id-type="pmid">34847837</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>C</given-names></name><name><surname>Luo</surname><given-names>X</given-names></name><name><surname>Zhan</surname><given-names>X</given-names></name><name><surname>Hao</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>YB LS,</surname></name><etal/></person-group><article-title>Comparative metabolomics reveals the metabolic variations between two endangered Taxus species (<italic>T</italic>. <italic>fuana</italic> and <italic>T</italic>. <italic>yunnanensis</italic>) in the Himalayas</article-title><source>BMC Plant Biol</source><year>2018</year><volume>18</volume><issue>1</issue><fpage>197</fpage><pub-id pub-id-type="doi">10.1186/s12870-018-1412-4</pub-id><pub-id pub-id-type="pmid">30223770</pub-id>
</element-citation><mixed-citation id="mc-CR18" publication-type="journal">Yu C, Luo X, Zhan X, Hao J, Zhang L, YB LS, et al. Comparative metabolomics reveals the metabolic variations between two endangered Taxus species (<italic>T</italic>. <italic>fuana</italic> and <italic>T</italic>. <italic>yunnanensis</italic>) in the Himalayas. BMC Plant Biol. 2018;18(1):197.<pub-id pub-id-type="pmid">30223770</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Fang</surname><given-names>J</given-names></name><name><surname>Qi</surname><given-names>X</given-names></name><name><surname>Lin</surname><given-names>M</given-names></name><name><surname>Zhong</surname><given-names>Y</given-names></name><name><surname>Sun</surname><given-names>L</given-names></name><etal/></person-group><article-title>Combined analysis of the fruit metabolome and transcriptome reveals candidate genes involved in flavonoid biosynthesis in <italic>Actinidia</italic>
<italic>arguta</italic></article-title><source>Int J Mol Sci</source><year>2018</year><volume>19</volume><issue>5</issue><fpage>1471</fpage><pub-id pub-id-type="doi">10.3390/ijms19051471</pub-id><pub-id pub-id-type="pmid">29762529</pub-id>
</element-citation><mixed-citation id="mc-CR19" publication-type="journal">Li Y, Fang J, Qi X, Lin M, Zhong Y, Sun L, et al. Combined analysis of the fruit metabolome and transcriptome reveals candidate genes involved in flavonoid biosynthesis in <italic>Actinidia</italic><italic>arguta</italic>. Int J Mol Sci. 2018;19(5):1471.<pub-id pub-id-type="pmid">29762529</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name><surname>Hallek</surname><given-names>M</given-names></name><name><surname>Cheson</surname><given-names>BD</given-names></name><name><surname>Catovsky</surname><given-names>D</given-names></name><name><surname>Caligaris-Cappio</surname><given-names>F</given-names></name><name><surname>Dighiero</surname><given-names>G</given-names></name><name><surname>Dohner</surname><given-names>H</given-names></name><etal/></person-group><article-title>Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on chronic lymphocytic leukemia updating the National Cancer Institute-Working Group 1996 guidelines</article-title><source>Blood</source><year>2008</year><volume>111</volume><issue>12</issue><fpage>5446</fpage><lpage>5456</lpage><pub-id pub-id-type="doi">10.1182/blood-2007-06-093906</pub-id><pub-id pub-id-type="pmid">18216293</pub-id>
</element-citation><mixed-citation id="mc-CR20" publication-type="journal">Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Dohner H, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on chronic lymphocytic leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008;111(12):5446&#x02013;56.<pub-id pub-id-type="pmid">18216293</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name><surname>Han</surname><given-names>Y</given-names></name><name><surname>Hu</surname><given-names>X</given-names></name><name><surname>Yun</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Tian</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Nucleolar and spindle associated protein 1 enhances chemoresistance through DNA damage repair pathway in chronic lymphocytic leukemia by binding with RAD51</article-title><source>Cell Death Dis</source><year>2021</year><volume>12</volume><issue>11</issue><fpage>1083</fpage><pub-id pub-id-type="doi">10.1038/s41419-021-04368-2</pub-id><pub-id pub-id-type="pmid">34782617</pub-id>
</element-citation><mixed-citation id="mc-CR21" publication-type="journal">Han Y, Hu X, Yun X, Liu J, Yang J, Tian Z, et al. Nucleolar and spindle associated protein 1 enhances chemoresistance through DNA damage repair pathway in chronic lymphocytic leukemia by binding with RAD51. Cell Death Dis. 2021;12(11):1083.<pub-id pub-id-type="pmid">34782617</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>X</given-names></name><name><surname>Han</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Tian</surname><given-names>Z</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><etal/></person-group><article-title>CTP synthase 2 predicts inferior survival and mediates DNA damage response via interacting with BRCA1 in chronic lymphocytic leukemia</article-title><source>Exp Hematol Oncol</source><year>2023</year><volume>12</volume><issue>1</issue><fpage>6</fpage><pub-id pub-id-type="doi">10.1186/s40164-022-00364-0</pub-id><pub-id pub-id-type="pmid">36635772</pub-id>
</element-citation><mixed-citation id="mc-CR22" publication-type="journal">Hu X, Han Y, Liu J, Wang H, Tian Z, Zhang X, et al. CTP synthase 2 predicts inferior survival and mediates DNA damage response via interacting with BRCA1 in chronic lymphocytic leukemia. Exp Hematol Oncol. 2023;12(1):6.<pub-id pub-id-type="pmid">36635772</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Zhou</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Lu</surname><given-names>K</given-names></name><name><surname>Li</surname><given-names>P</given-names></name><etal/></person-group><article-title>Inhibition of maternal embryonic leucine zipper kinase with OTSSP167 displays potent anti-leukemic effects in chronic lymphocytic leukemia</article-title><source>Oncogene</source><year>2018</year><volume>37</volume><issue>41</issue><fpage>5520</fpage><lpage>5533</lpage><pub-id pub-id-type="doi">10.1038/s41388-018-0333-x</pub-id><pub-id pub-id-type="pmid">29895969</pub-id>
</element-citation><mixed-citation id="mc-CR23" publication-type="journal">Zhang Y, Zhou X, Li Y, Xu Y, Lu K, Li P, et al. Inhibition of maternal embryonic leucine zipper kinase with OTSSP167 displays potent anti-leukemic effects in chronic lymphocytic leukemia. Oncogene. 2018;37(41):5520&#x02013;33.<pub-id pub-id-type="pmid">29895969</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name><surname>Keerthana</surname><given-names>CK</given-names></name><name><surname>Rayginia</surname><given-names>TP</given-names></name><name><surname>Shifana</surname><given-names>SC</given-names></name><name><surname>Anto</surname><given-names>NP</given-names></name><name><surname>Kalimuthu</surname><given-names>K</given-names></name><name><surname>Isakov</surname><given-names>N</given-names></name><etal/></person-group><article-title>The role of AMPK in cancer metabolism and its impact on the immunomodulation of the tumor microenvironment</article-title><source>Front Immunol</source><year>2023</year><volume>14</volume><fpage>1114582</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2023.1114582</pub-id><pub-id pub-id-type="pmid">36875093</pub-id>
</element-citation><mixed-citation id="mc-CR24" publication-type="journal">Keerthana CK, Rayginia TP, Shifana SC, Anto NP, Kalimuthu K, Isakov N, et al. The role of AMPK in cancer metabolism and its impact on the immunomodulation of the tumor microenvironment. Front Immunol. 2023;14:1114582.<pub-id pub-id-type="pmid">36875093</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name><surname>Avsec</surname><given-names>D</given-names></name><name><surname>Jakos Djordjevic</surname><given-names>AT</given-names></name><name><surname>Kanduser</surname><given-names>M</given-names></name><name><surname>Podgornik</surname><given-names>H</given-names></name><name><surname>Skerget</surname><given-names>M</given-names></name><name><surname>Mlinaric-Rascan</surname><given-names>I</given-names></name></person-group><article-title>Targeting autophagy triggers apoptosis and complements the action of venetoclax in chronic lymphocytic leukemia cells</article-title><source>Cancers (Basel).</source><year>2021</year><volume>13</volume><issue>18</issue><fpage>4557</fpage><pub-id pub-id-type="doi">10.3390/cancers13184557</pub-id><pub-id pub-id-type="pmid">34572784</pub-id>
</element-citation><mixed-citation id="mc-CR25" publication-type="journal">Avsec D, Jakos Djordjevic AT, Kanduser M, Podgornik H, Skerget M, Mlinaric-Rascan I. Targeting autophagy triggers apoptosis and complements the action of venetoclax in chronic lymphocytic leukemia cells. Cancers (Basel). 2021;13(18):4557.<pub-id pub-id-type="pmid">34572784</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name><surname>Verrelli</surname><given-names>D</given-names></name><name><surname>Dallera</surname><given-names>L</given-names></name><name><surname>Stendardo</surname><given-names>M</given-names></name><name><surname>Monzani</surname><given-names>S</given-names></name><name><surname>Pasqualato</surname><given-names>S</given-names></name><name><surname>Giorgio</surname><given-names>M</given-names></name><etal/></person-group><article-title>Hydroxycitric acid inhibits chronic myelogenous leukemia growth through activation of AMPK and mTOR pathway</article-title><source>Nutrients</source><year>2022</year><volume>14</volume><issue>13</issue><fpage>2669</fpage><pub-id pub-id-type="doi">10.3390/nu14132669</pub-id><pub-id pub-id-type="pmid">35807850</pub-id>
</element-citation><mixed-citation id="mc-CR26" publication-type="journal">Verrelli D, Dallera L, Stendardo M, Monzani S, Pasqualato S, Giorgio M, et al. Hydroxycitric acid inhibits chronic myelogenous leukemia growth through activation of AMPK and mTOR pathway. Nutrients. 2022;14(13):2669.<pub-id pub-id-type="pmid">35807850</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name><surname>Sah</surname><given-names>JP</given-names></name><name><surname>Hao</surname><given-names>NTT</given-names></name><name><surname>Han</surname><given-names>X</given-names></name><name><surname>Tran</surname><given-names>TTT</given-names></name><name><surname>McCarthy</surname><given-names>S</given-names></name><name><surname>Oh</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Ectonucleotide pyrophosphatase 2 (ENPP2) plays a crucial role in myogenic differentiation through the regulation by WNT/&#x003b2;-Catenin signaling</article-title><source>Int J Biochemi Cell Biol</source><year>2020</year><volume>118</volume><fpage>105661</fpage><pub-id pub-id-type="doi">10.1016/j.biocel.2019.105661</pub-id></element-citation><mixed-citation id="mc-CR27" publication-type="journal">Sah JP, Hao NTT, Han X, Tran TTT, McCarthy S, Oh Y, et al. Ectonucleotide pyrophosphatase 2 (ENPP2) plays a crucial role in myogenic differentiation through the regulation by WNT/&#x003b2;-Catenin signaling. Int J Biochemi Cell Biol. 2020;118:105661.</mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name><surname>Prieto</surname><given-names>D</given-names></name><name><surname>Seija</surname><given-names>N</given-names></name><name><surname>Uriepero</surname><given-names>A</given-names></name><name><surname>Souto-Padron</surname><given-names>T</given-names></name><name><surname>Oliver</surname><given-names>C</given-names></name><name><surname>Irigoin</surname><given-names>V</given-names></name><etal/></person-group><article-title>LPL protein in chronic lymphocytic leukaemia have different origins in mutated and unmutated patients. Advances for a new prognostic marker in CLL</article-title><source>Br J Haematol</source><year>2018</year><volume>182</volume><issue>4</issue><fpage>521</fpage><lpage>525</lpage><pub-id pub-id-type="doi">10.1111/bjh.15427</pub-id><pub-id pub-id-type="pmid">29953583</pub-id>
</element-citation><mixed-citation id="mc-CR28" publication-type="journal">Prieto D, Seija N, Uriepero A, Souto-Padron T, Oliver C, Irigoin V, et al. LPL protein in chronic lymphocytic leukaemia have different origins in mutated and unmutated patients. Advances for a new prognostic marker in CLL. Br J Haematol. 2018;182(4):521&#x02013;5.<pub-id pub-id-type="pmid">29953583</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name><surname>Rozovski</surname><given-names>U</given-names></name><name><surname>Grgurevic</surname><given-names>S</given-names></name><name><surname>Bueso-Ramos</surname><given-names>C</given-names></name><name><surname>Harris</surname><given-names>DM</given-names></name><name><surname>Li</surname><given-names>P</given-names></name><name><surname>Liu</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Aberrant LPL expression, driven by STAT3, mediates free fatty acid metabolism in CLL cells</article-title><source>Mol Cancer Res</source><year>2015</year><volume>13</volume><issue>5</issue><fpage>944</fpage><lpage>953</lpage><pub-id pub-id-type="doi">10.1158/1541-7786.MCR-14-0412</pub-id><pub-id pub-id-type="pmid">25733697</pub-id>
</element-citation><mixed-citation id="mc-CR29" publication-type="journal">Rozovski U, Grgurevic S, Bueso-Ramos C, Harris DM, Li P, Liu Z, et al. Aberrant LPL expression, driven by STAT3, mediates free fatty acid metabolism in CLL cells. Mol Cancer Res. 2015;13(5):944&#x02013;53.<pub-id pub-id-type="pmid">25733697</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>Z</given-names></name><name><surname>Gu</surname><given-names>D</given-names></name><name><surname>Wang</surname><given-names>R</given-names></name><name><surname>Zuo</surname><given-names>X</given-names></name><name><surname>Zhu</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><etal/></person-group><article-title>CircRIC8B regulates the lipid metabolism of chronic lymphocytic leukemia through miR199b-5p/LPL axis</article-title><source>Exp Hematol Oncol</source><year>2022</year><volume>11</volume><issue>1</issue><fpage>51</fpage><pub-id pub-id-type="doi">10.1186/s40164-022-00302-0</pub-id><pub-id pub-id-type="pmid">36064433</pub-id>
</element-citation><mixed-citation id="mc-CR30" publication-type="journal">Wu Z, Gu D, Wang R, Zuo X, Zhu H, Wang L, et al. CircRIC8B regulates the lipid metabolism of chronic lymphocytic leukemia through miR199b-5p/LPL axis. Exp Hematol Oncol. 2022;11(1):51.<pub-id pub-id-type="pmid">36064433</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name><surname>Karshovska</surname><given-names>E</given-names></name><name><surname>Mohibullah</surname><given-names>R</given-names></name><name><surname>Zhu</surname><given-names>M</given-names></name><name><surname>Zahedi</surname><given-names>F</given-names></name><name><surname>Thomas</surname><given-names>D</given-names></name><name><surname>Magkrioti</surname><given-names>C</given-names></name><etal/></person-group><article-title>Endothelial ENPP2 (ectonucleotide pyrophosphatase/phosphodiesterase 2) increases atherosclerosis in female and male mice</article-title><source>Arterioscler Thromb Vasc Biol</source><year>2022</year><volume>42</volume><issue>8</issue><fpage>1023</fpage><lpage>1036</lpage><pub-id pub-id-type="doi">10.1161/ATVBAHA.122.317682</pub-id><pub-id pub-id-type="pmid">35708027</pub-id>
</element-citation><mixed-citation id="mc-CR31" publication-type="journal">Karshovska E, Mohibullah R, Zhu M, Zahedi F, Thomas D, Magkrioti C, et al. Endothelial ENPP2 (ectonucleotide pyrophosphatase/phosphodiesterase 2) increases atherosclerosis in female and male mice. Arterioscler Thromb Vasc Biol. 2022;42(8):1023&#x02013;36.<pub-id pub-id-type="pmid">35708027</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name><surname>Plastira</surname><given-names>I</given-names></name><name><surname>Bernhart</surname><given-names>E</given-names></name><name><surname>Joshi</surname><given-names>L</given-names></name><name><surname>Koyani</surname><given-names>CN</given-names></name><name><surname>Strohmaier</surname><given-names>H</given-names></name><name><surname>Reicher</surname><given-names>H</given-names></name><etal/></person-group><article-title>MAPK signaling determines lysophosphatidic acid (LPA)-induced inflammation in microglia</article-title><source>J Neuroinflamm</source><year>2020</year><volume>17</volume><issue>1</issue><fpage>1</fpage><pub-id pub-id-type="doi">10.1186/s12974-020-01809-1</pub-id></element-citation><mixed-citation id="mc-CR32" publication-type="journal">Plastira I, Bernhart E, Joshi L, Koyani CN, Strohmaier H, Reicher H, et al. MAPK signaling determines lysophosphatidic acid (LPA)-induced inflammation in microglia. J Neuroinflamm. 2020;17(1):1.</mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>H-L</given-names></name><name><surname>Lai</surname><given-names>Z-Z</given-names></name><name><surname>Shi</surname><given-names>J-W</given-names></name><name><surname>Zhou</surname><given-names>W-J</given-names></name><name><surname>Mei</surname><given-names>J</given-names></name><name><surname>Ye</surname><given-names>J-F</given-names></name><etal/></person-group><article-title>A defective lysophosphatidic acid-autophagy axis increases miscarriage risk by restricting decidual macrophage residence</article-title><source>Autophagy</source><year>2022</year><volume>18</volume><issue>10</issue><fpage>2459</fpage><lpage>2480</lpage><pub-id pub-id-type="doi">10.1080/15548627.2022.2039000</pub-id><pub-id pub-id-type="pmid">35220880</pub-id>
</element-citation><mixed-citation id="mc-CR33" publication-type="journal">Yang H-L, Lai Z-Z, Shi J-W, Zhou W-J, Mei J, Ye J-F, et al. A defective lysophosphatidic acid-autophagy axis increases miscarriage risk by restricting decidual macrophage residence. Autophagy. 2022;18(10):2459&#x02013;80.<pub-id pub-id-type="pmid">35220880</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name><surname>Salgado-Polo</surname><given-names>F</given-names></name><name><surname>Borza</surname><given-names>R</given-names></name><name><surname>Matsoukas</surname><given-names>M-T</given-names></name><name><surname>Marsais</surname><given-names>F</given-names></name><name><surname>Jagerschmidt</surname><given-names>C</given-names></name><name><surname>Waeckel</surname><given-names>L</given-names></name><etal/></person-group><article-title>Autotaxin facilitates selective LPA receptor signaling</article-title><source>Cell Chem Biol</source><year>2023</year><volume>30</volume><issue>1</issue><fpage>69</fpage><lpage>84.e14</lpage><pub-id pub-id-type="doi">10.1016/j.chembiol.2022.12.006</pub-id><pub-id pub-id-type="pmid">36640760</pub-id>
</element-citation><mixed-citation id="mc-CR34" publication-type="journal">Salgado-Polo F, Borza R, Matsoukas M-T, Marsais F, Jagerschmidt C, Waeckel L, et al. Autotaxin facilitates selective LPA receptor signaling. Cell Chem Biol. 2023;30(1):69-84.e14.<pub-id pub-id-type="pmid">36640760</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name><surname>Yan</surname><given-names>J</given-names></name><name><surname>Duan</surname><given-names>W</given-names></name><name><surname>Gao</surname><given-names>Q</given-names></name><name><surname>Mao</surname><given-names>T</given-names></name><name><surname>Wang</surname><given-names>M</given-names></name><name><surname>Duan</surname><given-names>J</given-names></name><etal/></person-group><article-title>ENPP2 inhibitor improves proliferation in AOM/DSS-induced colorectal cancer mice via remodeling the gut barrier function and gut microbiota composition</article-title><source>Pharmacol Res</source><year>2023</year><volume>195</volume><fpage>106877</fpage><pub-id pub-id-type="doi">10.1016/j.phrs.2023.106877</pub-id><pub-id pub-id-type="pmid">37524154</pub-id>
</element-citation><mixed-citation id="mc-CR35" publication-type="journal">Yan J, Duan W, Gao Q, Mao T, Wang M, Duan J, et al. ENPP2 inhibitor improves proliferation in AOM/DSS-induced colorectal cancer mice via remodeling the gut barrier function and gut microbiota composition. Pharmacol Res. 2023;195:106877.<pub-id pub-id-type="pmid">37524154</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36.</label><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name><surname>Magkrioti</surname><given-names>C</given-names></name><name><surname>Kaffe</surname><given-names>E</given-names></name><name><surname>Aidinis</surname><given-names>V</given-names></name></person-group><article-title>The role of autotaxin and LPA signaling in embryonic development, pathophysiology and cancer</article-title><source>Int J Mol Sci</source><year>2023</year><volume>24</volume><issue>9</issue><fpage>8325</fpage><pub-id pub-id-type="doi">10.3390/ijms24098325</pub-id><pub-id pub-id-type="pmid">37176032</pub-id>
</element-citation><mixed-citation id="mc-CR36" publication-type="journal">Magkrioti C, Kaffe E, Aidinis V. The role of autotaxin and LPA signaling in embryonic development, pathophysiology and cancer. Int J Mol Sci. 2023;24(9):8325.<pub-id pub-id-type="pmid">37176032</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR37"><label>37.</label><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name><surname>Lim</surname><given-names>SA</given-names></name><name><surname>Su</surname><given-names>W</given-names></name><name><surname>Chapman</surname><given-names>NM</given-names></name><name><surname>Chi</surname><given-names>H</given-names></name></person-group><article-title>Lipid metabolism in T cell signaling and function</article-title><source>Nat Chem Biol</source><year>2022</year><volume>18</volume><issue>5</issue><fpage>470</fpage><lpage>481</lpage><pub-id pub-id-type="doi">10.1038/s41589-022-01017-3</pub-id><pub-id pub-id-type="pmid">35484263</pub-id>
</element-citation><mixed-citation id="mc-CR37" publication-type="journal">Lim SA, Su W, Chapman NM, Chi H. Lipid metabolism in T cell signaling and function. Nat Chem Biol. 2022;18(5):470&#x02013;81.<pub-id pub-id-type="pmid">35484263</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR38"><label>38.</label><citation-alternatives><element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name><surname>Butler</surname><given-names>FM</given-names></name><name><surname>Utt</surname><given-names>J</given-names></name><name><surname>Mathew</surname><given-names>RO</given-names></name><name><surname>Casiano</surname><given-names>CA</given-names></name><name><surname>Montgomery</surname><given-names>S</given-names></name><name><surname>Wiafe</surname><given-names>SA</given-names></name><etal/></person-group><article-title>Plasma metabolomics profiles in black and white participants of the adventist health study-2 cohort</article-title><source>BMC Med</source><year>2023</year><volume>21</volume><issue>1</issue><fpage>408</fpage><pub-id pub-id-type="doi">10.1186/s12916-023-03101-4</pub-id><pub-id pub-id-type="pmid">37904137</pub-id>
</element-citation><mixed-citation id="mc-CR38" publication-type="journal">Butler FM, Utt J, Mathew RO, Casiano CA, Montgomery S, Wiafe SA, et al. Plasma metabolomics profiles in black and white participants of the adventist health study-2 cohort. BMC Med. 2023;21(1):408.<pub-id pub-id-type="pmid">37904137</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR39"><label>39.</label><citation-alternatives><element-citation id="ec-CR39" publication-type="journal"><person-group person-group-type="author"><name><surname>Moore</surname><given-names>SC</given-names></name></person-group><article-title>Metabolomics and breast cancer: scaling up for robust results</article-title><source>BMC Med</source><year>2020</year><volume>18</volume><issue>1</issue><fpage>18</fpage><pub-id pub-id-type="doi">10.1186/s12916-019-1484-5</pub-id><pub-id pub-id-type="pmid">32000763</pub-id>
</element-citation><mixed-citation id="mc-CR39" publication-type="journal">Moore SC. Metabolomics and breast cancer: scaling up for robust results. BMC Med. 2020;18(1):18.<pub-id pub-id-type="pmid">32000763</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR40"><label>40.</label><citation-alternatives><element-citation id="ec-CR40" publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Mir</surname><given-names>SA</given-names></name><name><surname>Bendt</surname><given-names>AK</given-names></name><name><surname>Chua</surname><given-names>EWL</given-names></name><name><surname>Narasimhan</surname><given-names>K</given-names></name><name><surname>Tan</surname><given-names>KM-L</given-names></name><etal/></person-group><article-title>Plasma lipidomic profiling reveals metabolic adaptations to pregnancy and signatures of cardiometabolic risk: a preconception and longitudinal cohort study</article-title><source>BMC Med</source><year>2023</year><volume>21</volume><issue>1</issue><fpage>53</fpage><pub-id pub-id-type="doi">10.1186/s12916-023-02740-x</pub-id><pub-id pub-id-type="pmid">36782297</pub-id>
</element-citation><mixed-citation id="mc-CR40" publication-type="journal">Chen L, Mir SA, Bendt AK, Chua EWL, Narasimhan K, Tan KM-L, et al. Plasma lipidomic profiling reveals metabolic adaptations to pregnancy and signatures of cardiometabolic risk: a preconception and longitudinal cohort study. BMC Med. 2023;21(1):53.<pub-id pub-id-type="pmid">36782297</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR41"><label>41.</label><citation-alternatives><element-citation id="ec-CR41" publication-type="journal"><person-group person-group-type="author"><name><surname>Altuna-Coy</surname><given-names>A</given-names></name><name><surname>Ruiz-Plazas</surname><given-names>X</given-names></name><name><surname>S&#x000e1;nchez-Martin</surname><given-names>S</given-names></name><name><surname>Ascaso-Til</surname><given-names>H</given-names></name><name><surname>Prados-Saavedra</surname><given-names>M</given-names></name><name><surname>Alves-Santiago</surname><given-names>M</given-names></name><etal/></person-group><article-title>The lipidomic profile of the tumoral periprostatic adipose tissue reveals alterations in tumor cell&#x02019;s metabolic crosstalk</article-title><source>BMC Med</source><year>2022</year><volume>20</volume><issue>1</issue><fpage>255</fpage><pub-id pub-id-type="doi">10.1186/s12916-022-02457-3</pub-id><pub-id pub-id-type="pmid">35978404</pub-id>
</element-citation><mixed-citation id="mc-CR41" publication-type="journal">Altuna-Coy A, Ruiz-Plazas X, S&#x000e1;nchez-Martin S, Ascaso-Til H, Prados-Saavedra M, Alves-Santiago M, et al. The lipidomic profile of the tumoral periprostatic adipose tissue reveals alterations in tumor cell&#x02019;s metabolic crosstalk. BMC Med. 2022;20(1):255.<pub-id pub-id-type="pmid">35978404</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR42"><label>42.</label><citation-alternatives><element-citation id="ec-CR42" publication-type="journal"><person-group person-group-type="author"><name><surname>Zheng</surname><given-names>J-S</given-names></name><name><surname>Sharp</surname><given-names>SJ</given-names></name><name><surname>Imamura</surname><given-names>F</given-names></name><name><surname>Koulman</surname><given-names>A</given-names></name><name><surname>Schulze</surname><given-names>MB</given-names></name><name><surname>Ye</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Association between plasma phospholipid saturated fatty acids and metabolic markers of lipid, hepatic, inflammation and glycaemic pathways in eight European countries: a cross-sectional analysis in the EPIC-InterAct study</article-title><source>BMC Med</source><year>2017</year><volume>15</volume><issue>1</issue><fpage>2</fpage><pub-id pub-id-type="doi">10.1186/s12916-017-0968-4</pub-id><pub-id pub-id-type="pmid">28049531</pub-id>
</element-citation><mixed-citation id="mc-CR42" publication-type="journal">Zheng J-S, Sharp SJ, Imamura F, Koulman A, Schulze MB, Ye Z, et al. Association between plasma phospholipid saturated fatty acids and metabolic markers of lipid, hepatic, inflammation and glycaemic pathways in eight European countries: a cross-sectional analysis in the EPIC-InterAct study. BMC Med. 2017;15(1):2.<pub-id pub-id-type="pmid">28049531</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR43"><label>43.</label><citation-alternatives><element-citation id="ec-CR43" publication-type="journal"><person-group person-group-type="author"><name><surname>Rozovski</surname><given-names>U</given-names></name><name><surname>Hazan-Halevy</surname><given-names>I</given-names></name><name><surname>Barzilai</surname><given-names>M</given-names></name><name><surname>Keating</surname><given-names>MJ</given-names></name><name><surname>Estrov</surname><given-names>Z</given-names></name></person-group><article-title>Metabolism pathways in chronic lymphocytic leukemia</article-title><source>Leuk Lymphoma</source><year>2016</year><volume>57</volume><issue>4</issue><fpage>758</fpage><lpage>765</lpage><pub-id pub-id-type="doi">10.3109/10428194.2015.1106533</pub-id><pub-id pub-id-type="pmid">26643954</pub-id>
</element-citation><mixed-citation id="mc-CR43" publication-type="journal">Rozovski U, Hazan-Halevy I, Barzilai M, Keating MJ, Estrov Z. Metabolism pathways in chronic lymphocytic leukemia. Leuk Lymphoma. 2016;57(4):758&#x02013;65.<pub-id pub-id-type="pmid">26643954</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR44"><label>44.</label><citation-alternatives><element-citation id="ec-CR44" publication-type="journal"><person-group person-group-type="author"><name><surname>Pallasch</surname><given-names>CP</given-names></name><name><surname>Schwamb</surname><given-names>J</given-names></name><name><surname>Konigs</surname><given-names>S</given-names></name><name><surname>Schulz</surname><given-names>A</given-names></name><name><surname>Debey</surname><given-names>S</given-names></name><name><surname>Kofler</surname><given-names>D</given-names></name><etal/></person-group><article-title>Targeting lipid metabolism by the lipoprotein lipase inhibitor orlistat results in apoptosis of B-cell chronic lymphocytic leukemia cells</article-title><source>Leukemia</source><year>2008</year><volume>22</volume><issue>3</issue><fpage>585</fpage><lpage>592</lpage><pub-id pub-id-type="doi">10.1038/sj.leu.2405058</pub-id><pub-id pub-id-type="pmid">18079738</pub-id>
</element-citation><mixed-citation id="mc-CR44" publication-type="journal">Pallasch CP, Schwamb J, Konigs S, Schulz A, Debey S, Kofler D, et al. Targeting lipid metabolism by the lipoprotein lipase inhibitor orlistat results in apoptosis of B-cell chronic lymphocytic leukemia cells. Leukemia. 2008;22(3):585&#x02013;92.<pub-id pub-id-type="pmid">18079738</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR45"><label>45.</label><citation-alternatives><element-citation id="ec-CR45" publication-type="journal"><person-group person-group-type="author"><name><surname>Chattopadhyay</surname><given-names>A</given-names></name><name><surname>Mukherjee</surname><given-names>P</given-names></name><name><surname>Sulaiman</surname><given-names>D</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Girjalva</surname><given-names>V</given-names></name><name><surname>Dorreh</surname><given-names>N</given-names></name><etal/></person-group><article-title>Role of enterocyte Enpp2 and autotaxin in regulating lipopolysaccharide levels, systemic inflammation, and atherosclerosis</article-title><source>J Lipid Res</source><year>2023</year><volume>64</volume><issue>5</issue><fpage>100370</fpage><pub-id pub-id-type="doi">10.1016/j.jlr.2023.100370</pub-id><pub-id pub-id-type="pmid">37059333</pub-id>
</element-citation><mixed-citation id="mc-CR45" publication-type="journal">Chattopadhyay A, Mukherjee P, Sulaiman D, Wang H, Girjalva V, Dorreh N, et al. Role of enterocyte Enpp2 and autotaxin in regulating lipopolysaccharide levels, systemic inflammation, and atherosclerosis. J Lipid Res. 2023;64(5):100370.<pub-id pub-id-type="pmid">37059333</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR46"><label>46.</label><citation-alternatives><element-citation id="ec-CR46" publication-type="journal"><person-group person-group-type="author"><name><surname>Saulnier-Blache</surname><given-names>JS</given-names></name></person-group><article-title>Secretion and role of autotaxin and lysophosphatidic acid in adipose tissue</article-title><source>J Soc Biol</source><year>2006</year><volume>200</volume><issue>1</issue><fpage>77</fpage><lpage>81</lpage><pub-id pub-id-type="doi">10.1051/jbio:2006010</pub-id><pub-id pub-id-type="pmid">17144165</pub-id>
</element-citation><mixed-citation id="mc-CR46" publication-type="journal">Saulnier-Blache JS. Secretion and role of autotaxin and lysophosphatidic acid in adipose tissue. J Soc Biol. 2006;200(1):77&#x02013;81.<pub-id pub-id-type="pmid">17144165</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR47"><label>47.</label><citation-alternatives><element-citation id="ec-CR47" publication-type="journal"><person-group person-group-type="author"><name><surname>Panagopoulou</surname><given-names>M</given-names></name><name><surname>Fanidis</surname><given-names>D</given-names></name><name><surname>Aidinis</surname><given-names>V</given-names></name><name><surname>Chatzaki</surname><given-names>E</given-names></name></person-group><article-title>ENPP2 methylation in health and cancer</article-title><source>Int J Mol Sci</source><year>2021</year><volume>22</volume><issue>21</issue><fpage>11958</fpage><pub-id pub-id-type="doi">10.3390/ijms222111958</pub-id><pub-id pub-id-type="pmid">34769391</pub-id>
</element-citation><mixed-citation id="mc-CR47" publication-type="journal">Panagopoulou M, Fanidis D, Aidinis V, Chatzaki E. ENPP2 methylation in health and cancer. Int J Mol Sci. 2021;22(21):11958.<pub-id pub-id-type="pmid">34769391</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR48"><label>48.</label><citation-alternatives><element-citation id="ec-CR48" publication-type="journal"><person-group person-group-type="author"><name><surname>Panagopoulou</surname><given-names>M</given-names></name><name><surname>Drosouni</surname><given-names>A</given-names></name><name><surname>Fanidis</surname><given-names>D</given-names></name><name><surname>Karaglani</surname><given-names>M</given-names></name><name><surname>Balgkouranidou</surname><given-names>I</given-names></name><name><surname>Xenidis</surname><given-names>N</given-names></name><etal/></person-group><article-title>ENPP2 promoter methylation correlates with decreased gene expression in breast cancer: implementation as a liquid biopsy biomarker</article-title><source>Int J Mol Sci</source><year>2022</year><volume>23</volume><issue>7</issue><fpage>3717</fpage><pub-id pub-id-type="doi">10.3390/ijms23073717</pub-id><pub-id pub-id-type="pmid">35409077</pub-id>
</element-citation><mixed-citation id="mc-CR48" publication-type="journal">Panagopoulou M, Drosouni A, Fanidis D, Karaglani M, Balgkouranidou I, Xenidis N, et al. ENPP2 promoter methylation correlates with decreased gene expression in breast cancer: implementation as a liquid biopsy biomarker. Int J Mol Sci. 2022;23(7):3717.<pub-id pub-id-type="pmid">35409077</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR49"><label>49.</label><citation-alternatives><element-citation id="ec-CR49" publication-type="journal"><person-group person-group-type="author"><name><surname>Deng</surname><given-names>W</given-names></name><name><surname>Chen</surname><given-names>F</given-names></name><name><surname>Zhou</surname><given-names>Z</given-names></name><name><surname>Huang</surname><given-names>Y</given-names></name><name><surname>Lin</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>F</given-names></name><etal/></person-group><article-title>Hepatitis B virus promotes hepatocellular carcinoma progression synergistically with hepatic stellate cells via facilitating the expression and secretion of ENPP2</article-title><source>Front Mol Biosci</source><year>2021</year><volume>8</volume><fpage>745990</fpage><pub-id pub-id-type="doi">10.3389/fmolb.2021.745990</pub-id><pub-id pub-id-type="pmid">34805271</pub-id>
</element-citation><mixed-citation id="mc-CR49" publication-type="journal">Deng W, Chen F, Zhou Z, Huang Y, Lin J, Zhang F, et al. Hepatitis B virus promotes hepatocellular carcinoma progression synergistically with hepatic stellate cells via facilitating the expression and secretion of ENPP2. Front Mol Biosci. 2021;8: 745990.<pub-id pub-id-type="pmid">34805271</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR50"><label>50.</label><citation-alternatives><element-citation id="ec-CR50" publication-type="journal"><person-group person-group-type="author"><name><surname>Cholia</surname><given-names>RP</given-names></name><name><surname>Dhiman</surname><given-names>M</given-names></name><name><surname>Kumar</surname><given-names>R</given-names></name><name><surname>Mantha</surname><given-names>AK</given-names></name></person-group><article-title>Oxidative stress stimulates invasive potential in rat C6 and human U-87 MG glioblastoma cells via activation and cross-talk between PKM2, ENPP2 and APE1 enzymes</article-title><source>Metab Brain Dis</source><year>2018</year><volume>33</volume><issue>4</issue><fpage>1307</fpage><lpage>1326</lpage><pub-id pub-id-type="doi">10.1007/s11011-018-0233-3</pub-id><pub-id pub-id-type="pmid">29721771</pub-id>
</element-citation><mixed-citation id="mc-CR50" publication-type="journal">Cholia RP, Dhiman M, Kumar R, Mantha AK. Oxidative stress stimulates invasive potential in rat C6 and human U-87 MG glioblastoma cells via activation and cross-talk between PKM2, ENPP2 and APE1 enzymes. Metab Brain Dis. 2018;33(4):1307&#x02013;26.<pub-id pub-id-type="pmid">29721771</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR51"><label>51.</label><citation-alternatives><element-citation id="ec-CR51" publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>MH</given-names></name><name><surname>Seong</surname><given-names>JB</given-names></name><name><surname>Huh</surname><given-names>JW</given-names></name><name><surname>Bae</surname><given-names>YC</given-names></name><name><surname>Lee</surname><given-names>HS</given-names></name><name><surname>Lee</surname><given-names>DS</given-names></name></person-group><article-title>Peroxiredoxin 5 ameliorates obesity-induced non-alcoholic fatty liver disease through the regulation of oxidative stress and AMP-activated protein kinase signaling</article-title><source>Redox Biol</source><year>2020</year><volume>28</volume><fpage>101315</fpage><pub-id pub-id-type="doi">10.1016/j.redox.2019.101315</pub-id><pub-id pub-id-type="pmid">31505325</pub-id>
</element-citation><mixed-citation id="mc-CR51" publication-type="journal">Kim MH, Seong JB, Huh JW, Bae YC, Lee HS, Lee DS. Peroxiredoxin 5 ameliorates obesity-induced non-alcoholic fatty liver disease through the regulation of oxidative stress and AMP-activated protein kinase signaling. Redox Biol. 2020;28: 101315.<pub-id pub-id-type="pmid">31505325</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR52"><label>52.</label><citation-alternatives><element-citation id="ec-CR52" publication-type="journal"><person-group person-group-type="author"><name><surname>Garcia</surname><given-names>D</given-names></name><name><surname>Shaw</surname><given-names>RJ</given-names></name></person-group><article-title>AMPK: mechanisms of cellular energy sensing and restoration of metabolic balance</article-title><source>Mol Cell</source><year>2017</year><volume>66</volume><issue>6</issue><fpage>789</fpage><lpage>800</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2017.05.032</pub-id><pub-id pub-id-type="pmid">28622524</pub-id>
</element-citation><mixed-citation id="mc-CR52" publication-type="journal">Garcia D, Shaw RJ. AMPK: mechanisms of cellular energy sensing and restoration of metabolic balance. Mol Cell. 2017;66(6):789&#x02013;800.<pub-id pub-id-type="pmid">28622524</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR53"><label>53.</label><citation-alternatives><element-citation id="ec-CR53" publication-type="journal"><person-group person-group-type="author"><name><surname>Janzen</surname><given-names>NR</given-names></name><name><surname>Whitfield</surname><given-names>J</given-names></name><name><surname>Hoffman</surname><given-names>NJ</given-names></name></person-group><article-title>Interactive roles for AMPK and glycogen from cellular energy sensing to exercise metabolism</article-title><source>Int J Mol Sci</source><year>2018</year><volume>19</volume><issue>11</issue><fpage>3344</fpage><pub-id pub-id-type="doi">10.3390/ijms19113344</pub-id><pub-id pub-id-type="pmid">30373152</pub-id>
</element-citation><mixed-citation id="mc-CR53" publication-type="journal">Janzen NR, Whitfield J, Hoffman NJ. Interactive roles for AMPK and glycogen from cellular energy sensing to exercise metabolism. Int J Mol Sci. 2018;19(11):3344.<pub-id pub-id-type="pmid">30373152</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR54"><label>54.</label><citation-alternatives><element-citation id="ec-CR54" publication-type="journal"><person-group person-group-type="author"><name><surname>Prieto</surname><given-names>D</given-names></name><name><surname>Oppezzo</surname><given-names>P</given-names></name></person-group><article-title>Lipoprotein lipase expression in chronic lymphocytic leukemia: new insights into leukemic progression</article-title><source>Molecules</source><year>2017</year><volume>22</volume><issue>12</issue><fpage>2083</fpage><pub-id pub-id-type="doi">10.3390/molecules22122083</pub-id><pub-id pub-id-type="pmid">29206143</pub-id>
</element-citation><mixed-citation id="mc-CR54" publication-type="journal">Prieto D, Oppezzo P. Lipoprotein lipase expression in chronic lymphocytic leukemia: new insights into leukemic progression. Molecules. 2017;22(12):2083.<pub-id pub-id-type="pmid">29206143</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR55"><label>55.</label><citation-alternatives><element-citation id="ec-CR55" publication-type="journal"><person-group person-group-type="author"><name><surname>Rombout</surname><given-names>A</given-names></name><name><surname>Verhasselt</surname><given-names>B</given-names></name><name><surname>Philippe</surname><given-names>J</given-names></name></person-group><article-title>Lipoprotein lipase in chronic lymphocytic leukemia: function and prognostic implications</article-title><source>Eur J Haematol</source><year>2016</year><volume>97</volume><issue>5</issue><fpage>409</fpage><lpage>415</lpage><pub-id pub-id-type="doi">10.1111/ejh.12789</pub-id><pub-id pub-id-type="pmid">27504855</pub-id>
</element-citation><mixed-citation id="mc-CR55" publication-type="journal">Rombout A, Verhasselt B, Philippe J. Lipoprotein lipase in chronic lymphocytic leukemia: function and prognostic implications. Eur J Haematol. 2016;97(5):409&#x02013;15.<pub-id pub-id-type="pmid">27504855</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR56"><label>56.</label><citation-alternatives><element-citation id="ec-CR56" publication-type="journal"><person-group person-group-type="author"><name><surname>McCaw</surname><given-names>L</given-names></name><name><surname>Shi</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>G</given-names></name><name><surname>Li</surname><given-names>YJ</given-names></name><name><surname>Spaner</surname><given-names>DE</given-names></name></person-group><article-title>Low density lipoproteins amplify cytokine-signaling in chronic lymphocytic leukemia cells</article-title><source>EBioMedicine</source><year>2017</year><volume>15</volume><fpage>24</fpage><lpage>35</lpage><pub-id pub-id-type="doi">10.1016/j.ebiom.2016.11.033</pub-id><pub-id pub-id-type="pmid">27932296</pub-id>
</element-citation><mixed-citation id="mc-CR56" publication-type="journal">McCaw L, Shi Y, Wang G, Li YJ, Spaner DE. Low density lipoproteins amplify cytokine-signaling in chronic lymphocytic leukemia cells. EBioMedicine. 2017;15:24&#x02013;35.<pub-id pub-id-type="pmid">27932296</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR57"><label>57.</label><citation-alternatives><element-citation id="ec-CR57" publication-type="journal"><person-group person-group-type="author"><name><surname>Bhave</surname><given-names>SR</given-names></name><name><surname>Dadey</surname><given-names>DY</given-names></name><name><surname>Karvas</surname><given-names>RM</given-names></name><name><surname>Ferraro</surname><given-names>DJ</given-names></name><name><surname>Kotipatruni</surname><given-names>RP</given-names></name><name><surname>Jaboin</surname><given-names>JJ</given-names></name><etal/></person-group><article-title>Autotaxin inhibition with PF-8380 enhances the radiosensitivity of human and murine glioblastoma cell lines</article-title><source>Front Oncol</source><year>2013</year><volume>3</volume><fpage>236</fpage><pub-id pub-id-type="doi">10.3389/fonc.2013.00236</pub-id><pub-id pub-id-type="pmid">24062988</pub-id>
</element-citation><mixed-citation id="mc-CR57" publication-type="journal">Bhave SR, Dadey DY, Karvas RM, Ferraro DJ, Kotipatruni RP, Jaboin JJ, et al. Autotaxin inhibition with PF-8380 enhances the radiosensitivity of human and murine glioblastoma cell lines. Front Oncol. 2013;3:236.<pub-id pub-id-type="pmid">24062988</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR58"><label>58.</label><citation-alternatives><element-citation id="ec-CR58" publication-type="journal"><person-group person-group-type="author"><name><surname>Roy</surname><given-names>S</given-names></name><name><surname>Chakrabarti</surname><given-names>M</given-names></name><name><surname>Dasgupta</surname><given-names>H</given-names></name><name><surname>Mahale</surname><given-names>A</given-names></name><name><surname>Tripathi</surname><given-names>S</given-names></name><name><surname>Sharma</surname><given-names>V</given-names></name><etal/></person-group><article-title>Inhibition of autotaxin ameliorates LPA-mediated neuroinflammation and alleviates neurological dysfunction in acute hepatic encephalopathy</article-title><source>ACS Chem Neurosci</source><year>2022</year><volume>13</volume><issue>19</issue><fpage>2829</fpage><lpage>2841</lpage><pub-id pub-id-type="doi">10.1021/acschemneuro.2c00046</pub-id><pub-id pub-id-type="pmid">36112416</pub-id>
</element-citation><mixed-citation id="mc-CR58" publication-type="journal">Roy S, Chakrabarti M, Dasgupta H, Mahale A, Tripathi S, Sharma V, et al. Inhibition of autotaxin ameliorates LPA-mediated neuroinflammation and alleviates neurological dysfunction in acute hepatic encephalopathy. ACS Chem Neurosci. 2022;13(19):2829&#x02013;41.<pub-id pub-id-type="pmid">36112416</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR59"><label>59.</label><citation-alternatives><element-citation id="ec-CR59" publication-type="journal"><person-group person-group-type="author"><name><surname>D&#x02019;Souza</surname><given-names>K</given-names></name><name><surname>Kane</surname><given-names>DA</given-names></name><name><surname>Touaibia</surname><given-names>M</given-names></name><name><surname>Kershaw</surname><given-names>EE</given-names></name><name><surname>Pulinilkunnil</surname><given-names>T</given-names></name><name><surname>Kienesberger</surname><given-names>PC</given-names></name></person-group><article-title>Autotaxin is regulated by glucose and insulin in adipocytes</article-title><source>Endocrinology</source><year>2017</year><volume>158</volume><issue>4</issue><fpage>791</fpage><lpage>803</lpage><pub-id pub-id-type="doi">10.1210/en.2017-00035</pub-id><pub-id pub-id-type="pmid">28324037</pub-id>
</element-citation><mixed-citation id="mc-CR59" publication-type="journal">D&#x02019;Souza K, Kane DA, Touaibia M, Kershaw EE, Pulinilkunnil T, Kienesberger PC. Autotaxin is regulated by glucose and insulin in adipocytes. Endocrinology. 2017;158(4):791&#x02013;803.<pub-id pub-id-type="pmid">28324037</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR60"><label>60.</label><citation-alternatives><element-citation id="ec-CR60" publication-type="journal"><person-group person-group-type="author"><name><surname>Smolej</surname><given-names>L</given-names></name></person-group><article-title>Refractory chronic lymphocytic leukemia: a therapeutic challenge</article-title><source>Curr Cancer Drug Targets</source><year>2016</year><volume>16</volume><issue>8</issue><fpage>701</fpage><lpage>709</lpage><pub-id pub-id-type="doi">10.2174/1568009616666160408150032</pub-id><pub-id pub-id-type="pmid">27055577</pub-id>
</element-citation><mixed-citation id="mc-CR60" publication-type="journal">Smolej L. Refractory chronic lymphocytic leukemia: a therapeutic challenge. Curr Cancer Drug Targets. 2016;16(8):701&#x02013;9.<pub-id pub-id-type="pmid">27055577</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR61"><label>61.</label><citation-alternatives><element-citation id="ec-CR61" publication-type="journal"><person-group person-group-type="author"><name><surname>Skanland</surname><given-names>SS</given-names></name><name><surname>Karlsen</surname><given-names>L</given-names></name><name><surname>Tasken</surname><given-names>K</given-names></name></person-group><article-title>B cell signalling pathways-new targets for precision medicine in chronic lymphocytic leukaemia</article-title><source>Scand J Immunol</source><year>2020</year><volume>92</volume><issue>5</issue><fpage>e12931</fpage><pub-id pub-id-type="doi">10.1111/sji.12931</pub-id><pub-id pub-id-type="pmid">32640099</pub-id>
</element-citation><mixed-citation id="mc-CR61" publication-type="journal">Skanland SS, Karlsen L, Tasken K. B cell signalling pathways-new targets for precision medicine in chronic lymphocytic leukaemia. Scand J Immunol. 2020;92(5): e12931.<pub-id pub-id-type="pmid">32640099</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR62"><label>62.</label><citation-alternatives><element-citation id="ec-CR62" publication-type="journal"><person-group person-group-type="author"><name><surname>Busque</surname><given-names>L</given-names></name></person-group><article-title>HSPCs are marathon and not sprint relay athletes</article-title><source>Blood</source><year>2017</year><volume>129</volume><issue>11</issue><fpage>1406</fpage><lpage>1407</lpage><pub-id pub-id-type="doi">10.1182/blood-2017-02-763516</pub-id><pub-id pub-id-type="pmid">28302687</pub-id>
</element-citation><mixed-citation id="mc-CR62" publication-type="journal">Busque L. HSPCs are marathon and not sprint relay athletes. Blood. 2017;129(11):1406&#x02013;7.<pub-id pub-id-type="pmid">28302687</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR63"><label>63.</label><citation-alternatives><element-citation id="ec-CR63" publication-type="journal"><person-group person-group-type="author"><name><surname>George</surname><given-names>B</given-names></name><name><surname>Chowdhury</surname><given-names>SM</given-names></name><name><surname>Hart</surname><given-names>A</given-names></name><name><surname>Sircar</surname><given-names>A</given-names></name><name><surname>Singh</surname><given-names>SK</given-names></name><name><surname>Nath</surname><given-names>UK</given-names></name><etal/></person-group><article-title>Ibrutinib resistance mechanisms and treatment strategies for B-cell lymphomas</article-title><source>Cancers (Basel).</source><year>2020</year><volume>12</volume><issue>5</issue><fpage>1328</fpage><pub-id pub-id-type="doi">10.3390/cancers12051328</pub-id><pub-id pub-id-type="pmid">32455989</pub-id>
</element-citation><mixed-citation id="mc-CR63" publication-type="journal">George B, Chowdhury SM, Hart A, Sircar A, Singh SK, Nath UK, et al. Ibrutinib resistance mechanisms and treatment strategies for B-cell lymphomas. Cancers (Basel). 2020;12(5):1328.<pub-id pub-id-type="pmid">32455989</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR64"><label>64.</label><citation-alternatives><element-citation id="ec-CR64" publication-type="journal"><person-group person-group-type="author"><name><surname>Kaur</surname><given-names>V</given-names></name><name><surname>Swami</surname><given-names>A</given-names></name></person-group><article-title>Ibrutinib in CLL: a focus on adverse events, resistance, and novel approaches beyond ibrutinib</article-title><source>Ann Hematol</source><year>2017</year><volume>96</volume><issue>7</issue><fpage>1175</fpage><lpage>1184</lpage><pub-id pub-id-type="doi">10.1007/s00277-017-2973-2</pub-id><pub-id pub-id-type="pmid">28342031</pub-id>
</element-citation><mixed-citation id="mc-CR64" publication-type="journal">Kaur V, Swami A. Ibrutinib in CLL: a focus on adverse events, resistance, and novel approaches beyond ibrutinib. Ann Hematol. 2017;96(7):1175&#x02013;84.<pub-id pub-id-type="pmid">28342031</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR65"><label>65.</label><citation-alternatives><element-citation id="ec-CR65" publication-type="journal"><person-group person-group-type="author"><name><surname>Timofeeva</surname><given-names>N</given-names></name><name><surname>Gandhi</surname><given-names>V</given-names></name></person-group><article-title>Ibrutinib combinations in CLL therapy: scientific rationale and clinical results</article-title><source>Blood Cancer J</source><year>2021</year><volume>11</volume><issue>4</issue><fpage>79</fpage><pub-id pub-id-type="doi">10.1038/s41408-021-00467-7</pub-id><pub-id pub-id-type="pmid">33927183</pub-id>
</element-citation><mixed-citation id="mc-CR65" publication-type="journal">Timofeeva N, Gandhi V. Ibrutinib combinations in CLL therapy: scientific rationale and clinical results. Blood Cancer J. 2021;11(4):79.<pub-id pub-id-type="pmid">33927183</pub-id>
</mixed-citation></citation-alternatives></ref></ref-list></back></article>